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1 General introduction 
1.1 Background of the study 
Obstructive airway diseases (OAD) such as asthma and COPD are common 
chronic diseases, mainly diagnosed and treated in primary medical care, by 
general practitioners (GP's). A typical characteristic for chronic diseases is that 
it may take years before the disease becomes clinically evident. OAD presents 
itself with symptoms such as cough, sputum production, continuous or 
recurrent episodes of shortness of breath and wheeze, although the severity of 
these symptoms may vary from time to time. These symptoms may exist 
unnoticed or may even be consciously ignored by the sufferer as a temporary 
inconvenience. Through the years the underlying condition may progress into a 
clinically evident disease, eventually leading to disability. 
A = known to GP 
В =not known to GP 
/ A \ 
В \ 
<M^ 
Figure 1.1: The prevalence of asthma and COPD in the general population. 
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Although OAD is mainly diagnosed and treated by GP's, there is a discrepancy 
in prevalence rates between population surveys and morbidity registration 
systems in general practice. The reported (registered) prevalence of OAD is 
usually lower in general practice compared with that in population 
surveys.1'2'3-4 This indicates the presence of unregistered morbidity regarding 
OAD in the general population. The prevalence of OAD in the general population 
can therefore be compared to an ice-berg (Figure-1.1). The tip of the ice-berg 
(A) represents the registered morbidity. This constitutes patients known to the 
general practitioners including those treated by pulmonologists and specialized 
asthma centres. The submerged part (B) represents the unregistered morbidity. 
This unregistered morbidity has been suggested to be due to underdiagnosis by 
doctors5 and under-presentation by patients.8 Modern guidelines on diagnosis 
and treatment of asthma789·10·11 and COPD10·11·12·13·14 also aim at 
preventing underdiagnosis and eventual delays in treatment. However, under-
presentation forms an important barrier against implementing these guidelines. 
Active case-finding may be an important option in the case of under 
presentation. 
The guidelines encourage the use of objective lung function parameters in 
assessing patients with airway obstruction. This is because respiratory 
symptoms show a poor correlation with lung function.15,1β The annual rate of 
decline in forced expiratory volume in one second (FEV,) in adults is seen as the 
most important index for assessing severity, for estimating progression and for 
predicting mortality in asthma and COPD17. It has been documented that FEV, 
shows a physiological, linear decline after the age of 18-25 years.18·19 The 
rate of decline in FEV, is greater in patients with asthma and COPD in 
comparison to healthy subjects.13-20 Figure-1.2 shows the hypothetical model 
proposed by Fletcher,18 used in this study, to illustrate the course of FEV, with 
age. It represents the development of pulmonary function through growth to its 
maximum around 25-35 years. Segment AB represents the course of FEV, in 
normal adults with no obstructive airways disease. Segment AC on the other 
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hand is an exaggerated representation of a progressive decline in FEV1 seen in 
patients with obstructive airways disease. The point D represents the onset of 
disability (hypothetical value of 40% of the predicted FEV, considered as the 
threshold for the onset of disability). 
FEV1(%) 
10 20 30 40 50 60 70 80 90 100 
Age (years) 
Figure 1.2: Course of FEV, in relation to age. 
It has been documented that intervention (smoking cessation,18·21 use of 
inhaled corticosteroids22'23,2*) at for example point E, can reduce the 
progressive decline in FEV,, as depicted by segment EF. Proper intervention can 
therefore cause a delay (segment DG) in the hypothetical onset of disability. 
From this model it can be further hypothesized that treatment could be more 
effective if it is implemented at an earlier stage for example at point H (onset of 
disability at point J). However, there is to date no empirical evidence to support 
this hypothesis, regarding the observation of early onset of decline or regarding 
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the effects of early treatment. The first step would be to detect patients whose 
lung function would probably reach the level for onset of disability at a relatively 
young age. However, little is known on detecting such patients, preferably 
before the clinically evident form of the disease has occurred. 
The studies presented in this thesis form the first part of a long-term, 
prospective study designed to investigate detection, intervention and monitoring 
of COPD and asthma in the general population (DIMCA project). We focused our 
attention on the unregistered morbidity in the general population, i.e. the 
submerged part of the iceberg. Our aim was to detect patients who are probably 
at risk of attaining the onset of disability at a relatively young age by means of 
screening the general population for respiratory symptoms and lung function. 
Patients with a reduced FEV, as compared to the reference value (%FEV1) and 
those with signs of an increased annual rate of decline in FEV, were defined as 
probably being at risk. 
1.2 Screening the general population for OAD 
Screening has been defined as the identification of patients in a pre-clinical 
stage of the disease by means of a relatively simple diagnostic test.25 This 
with the aim of preventing the progression to the clinically manifest form of 
asthma or COPD consisting of serious, continuous or paroxysmal symptoms 
accompanied by (an irreversible) loss in lung function which eventually may 
necessitate hospitalization of the patient. It is therefore by definition a method 
of secondary prevention. The purpose of screening is to detect and treat 
subjects who are at risk for developing a clinically manifest form of asthma or 
COPD. This with the intention of preventing disability thereby improving quality 
of life on the long-run. 
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Justification of screening the general population for OAD 
Wilson and Jungner introduced criteria for screening.26 Although somewhat 
out-dated they are still relevant in considering the option of screening the 
general population for OAD. Applied to the current status of asthma and COPD 
this leads to the following position. 
a) Morbidity caused by asthma and COPO should be an important health 
issue in present times. 
With regard to the increased life-expectancy and thereby the aging of the 
population in industrialised countries, obstructive diseases of the airways could 
become an even greater problem in the near future.27 Therefore it is important 
to investigate methods of reducing this potential problem. Further investigations 
regarding this topic is therefore justified. The DIMCA project is an attempt to 
investigate the possibility of detecting individuals who are potentially at risk for 
developing asthma or COPD. This with the intention of adequately treating those 
at risk at an early stage, in order to prevent the clinically manifest form of the 
disease. This thesis concerns studies regarding this topic. 
b) The natural course of the disease and the pre-clinical stage should be well 
documented. 
The natural course of the disease is reasonably well documented.8'9 However, 
little is known on the pre-clinical stage of the disease. Further investigations 
regarding this topic is therefore justified. The DIMCA project collects longitudinal 
data on demographic characteristics of patients who are probably at risk. 
c) A valid instrument for detecting patients who are potentially at risk should 
be available. 
Although more attention has been focused on asthma and COPD in the past 
decade there is still evidence of undetected patients in the general population 
(the submerged part of the ice-berg). Therefore further investigation regarding to 
this topic can also be justified. The DIMCA project aims at documenting the 
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existence of undetected patients, investigating possible reasons for this 
existence and investigating methods for detecting such patients. The instrument 
under scrutiny during this study was the screening-test, consisting of a modified 
respiratory symptoms questionnaire and lung function indices, such as, FEV, 
and the percentage reversibility of the airway obstruction. The results are 
presented in this thesis. 
d) An effective method of treatment should be available. 
There is consensus on how to treat patients with asthma and to a lesser extent 
on how to treat patients with COPD.1"8 It is however not known whether 
patients detected actively at an early stage of the disease, by means of 
screening the general population, can be treated effectively. Therefore further 
investigation regarding to this topic can also be justified. The results are 
presented in this thesis. 
e) The practical implementation of early detection and treatment should be 
feasible in general practice. 
Once again little knowledge is available and the DIMCA project collects data on 
this subject under research conditions to judge feasibility and thereby the 
possibility for implementation. 
f) The method used for screening should be acceptable for the general 
population. 
The test should be simple, non-invasive and should not consume much time. 
Respiratory symptom questionnaires and spirometry which fulfil the above 
criteria were used during the screening. 
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g) The cost-effectiveness ratio of active case finding and treatment should 
be compared to current practice. 
A part of the DIMCA project consists of a cost-effectiveness analysis and aims 
at investigating this. 
h) The adverse effects due to screening should be well documented. 
The DIMCA project also collects data of a control-group that was not involved in 
the screening-survey. Comparison of these two groups can reveal information 
regarding adverse effects due to screening for example médicalisation of the 
general population. 
1.3 Aim of the DIMCA project 
From the above it can be summarized that there is a need for the early detection 
of OAD in the general population. It is also necessary to document the 
prevalence of undetected cases and to investigate the reasons for the existence 
of such a group. Improved standardized methods enabling the proper detection 
of patients at an early stage should be studied further. There is also a need to 
investigate the efficacy of treating patients detected by means of screening. 
Therefore, the aim of the DIMCA project was to answer the following questions 
regarding screening the general population for OAD. 
1.3.1 What is the prevalence of previously undiagnosed forms of OAD? i.e. 
patients with asthma or COPD who have not been identified as such by 
general practitioners and who constitute the submerged part of the 
iceberg (Chapter 2 and 3). 
The aim of Chapter two28 was to investigate the prevalence of OAD and the 
prevalence of undetected cases. It is also important to know whether the 
increased attention on asthma and COPD in the past decade has caused a 
decrease in the prevalence of the disease and the percentage of undetected 
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cases. We investigated this by means of comparing the results of our screening 
survey in 1992 to that of a screening survey in the same region (eastern part of 
the Netherlands) conducted in 1977. Data for this chapter were collected during 
the recruitment phase (1.4.1) and screening phase (section 1.4.2) as presented 
in the outline of the DIMCA project. 
In Chapter 3 we investigated possible reasons for the existence of the 
submerged part of the ice-berg. The influence of patient characteristics, such as 
the patients ability to perceive dyspnoea and the patients psychological profile, 
for consulting the GP in the event of respiratory symptoms were studied. Data 
for this chapter were collected during the screening phase (section 1.4.2) and 
monitor phase (section 1.4.3) as presented in the outline of the DIMCA project. 
1.3.2 Is it possible to detect subjects with a mild disease by means of screening 
the general population? (Chapter 4) 
The aim of the study presented in Chapter 4 was to investigate whether it is 
possible to detect subjects in the general population with a mild deterioration in 
FEV,, presumably as a result of progressive decline in lung function in the~past. 
Data for this chapter were collected during the screening phase (section 1.4.2) 
and intervention phase (section 1.4.4) as presented in the outline of the DIMCA 
project. Longitudinal data regarding the sample of healthy subjects were also 
used for this purpose. 
Studies based on progressive decline in FEV, constitutes the second part of the 
DIMCA project and will not be presented in this thesis. Data for this part were 
collected during the monitor phase (section 1.4.3) of the DIMCA project. 
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1.3.3 Is it possible to improve the standard respiratory symptoms questionnaire 
in order to detect subjects with an indication for treatment by means of a 
screening test (chapters). 
The aim of the study presented in Chapter 5 was to investigate the clinical 
relevance (diagnostic value) of questions regarding Bronchial 
Hyperresponsiveness (BHR) and allergy during a screening test in order to detect 
subjects with a mild OAD. These subjects were defined as having a reduced 
FEV, or a high bronchial hyperresponsiveness combined with a high percentage 
reversibility. Data for this chapter were collected during the screening phase 
(section 1.4.2) and intervention phase (section 1.4.4) as presented in the outline 
of the DIMCA project. 
1.3.4 Which lung function parameters should be monitored in OAD? (Chapters 6 
and 7) 
The aim of the study presented in Chapter 6 was to investigate the effect of the 
frequency of FEV, measurements and the duration of the observation period on 
the accuracy of the measured annual rate of decline of an individual. This with 
the intention of detecting patients with a rapid decline in lung function at an 
early stage. This analysis was performed by means of a model using simulated 
data based on mean lung function data (FEV, and SD) from the screening phase 
of the DIMCA project (section 1.4.2). 
The aim of the study presented in Chapter 7 was to investigate the long-term 
correlation between FEV, and Peak flow29. This chapter was based on data 
from a previous long-term projects (FCB30 and 1С22) concerning established 
asthmatic and COPD patients. These research projects were also conducted by 
the Department of General Practice of the University of Nijmegen. 
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1.3.5 What Is the effect of inhaled corticosteroids in treating patients with OAD 
who were actively detected by means of screening the general 
population? (Chapter 8) 
The aim of the study presented in Chapter 8 was to investigate the efficacy of 
inhaled steroids on lung function, bronchial hyperresponsiveness and respiratory 
symptoms in subjects with a mild OAD, actively detected by screening the 
general population. Subjects with a mild OAD were defined as having a reduced 
FEV, or a high bronchial hyperresponsiveness combined with a high percentage 
reversibility. Data for this chapter were collected during the intervention phase 
as presented in section 1.4.4 (outline of the DIMCA project). 
1.4 Outline of the DIMCA project 
Random sample 
n = 1 9 8 8 
At-risk 
η - 6 0 4 
Invited 
n = 1 7 4 9 
Screened 
n = 1 1 5 5 
Monitored 
η = 3 8 4 
Intervention 
η - 5 4 
No intervention 
η - 3 3 0 
Not at-risk 
n = 551 
Monitored 
η = 77 
Excluded 
η = 2 3 9 
Non-participants 
η = 594 
Screened 
η = 34 
Figure 1.3: Outline of present study 
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The study presented in this thesis constitutes the first part of a large survey on 
early detection and treatment of asthma and COPD (DIMCA project). For clarity 
the general design of the DIMCA project is summarized here. Figure-1.3 shows 
the main points related to the screening which have been presented in this 
thesis. 
1.4.1 Recruitment phase 
In order to extrapolate any findings of this study to the general population, it 
was necessary to recruit a random sample of adults representative of the 
general population in the eastern part of the Netherlands. As mentioned earlier 
asthma and COPD are mainly diagnosed and treated in general practice. In the 
Dutch health care system 98% of the inhabitants are registered at a general 
practice in their community of residence. The general practitioner is the provider 
of basic medical care to an average of 2500 persons and is the gateway to 
specialized care. Therefore, as the majority of the dutch population is registered 
at general practices, we used the practice registers for recruiting subjects. A 
random sample of 1988 adults between the ages 25 and 70 years were drawn 
from ten general practices. These practices were located in the same suburban 
region of the eastern part of the Netherlands. The GP's were asked to exclude 
all subjects with a serious disability or life threatening disease and those 
dependant on inhaled corticosteroids. This last group was excluded from 
screening as steroids are known to alter the normal course of lung function and 
symptoms in patients. In this way 239 subjects were excluded from further 
study. The remaining 1749 subjects were invited for the study. 594 subjects 
either refused to take part or did not respond to our invitation. A random sample 
of 34 subjects who initially refused to take part, consented to participate later, 
by taking a simplified version of the screening test at their own homes in order 
to investigate a possible recruitment bias. Results have been used for chapters 2 
and 4. 
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1.4.2 Screening phase 
1155 subjects who consented to take part were screened for respiratory 
symptoms and lung function at the office of the general practitioner. Subjects 
fulfilling at least one of the following four criteria were designated "probably at-
risk." 
Screening criteria 
1 : Presence of respiratory symptoms as measured by means of a respiratory 
symptoms questionnaire. 
2: Measured FEV, < reference value31 minus 1.64 standard deviation 
3: Reversibility of the FEV, after administering 800 ug salbutamol > 15% of 
the reference value. 
4: At least two of the following three items positive. 
i) Non-specific respiratory symptoms 
ii) Measured FEV, < reference value minus 1.0 SD. 
iii) Reversibility of FEV, between 10 and 15% of the reference value. 
604 subjects fulfilled at least one of the above four criteria. The remaining 551 
were designated as "not at risk" (healthy). Results have been used for chapters 
2, 3, 4, 5 and 8. 
1.4.3 Monitor phase 
Follow-up of subjects designated "probably at-risk." 
384 of the 604 "probably at risk" subjects volunteered to participate in the 
follow-up study (monitor phase). The symptom score and lung function were 
assessed once every three months during a period of two years. Subjects were 
therefore assessed on nine separate occasions. Measurement numbers 1, 5 and 
9 were conducted at the Department of Pulmonology, Dekkerswald by lung 
function technicians. Measurement numbers 2, 3, 4, 6, 7 and 8 were conducted 
at the surgery of the respective general practitioner by practice assistants. 
Results have been used for chapters 3, 5 and 8. 
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Follow-up of subjects designated "not at-risk (healthy)." 
A random sample of 77 of the 551 healthy subjects were also invited for a 
follow up study, as a control group in order to validate the screening procedure. 
Respiratory symptoms and lung function were assessed once every three 
months at their own homes during a period of two years. The results have been 
presented in chapter 4. 
1.4.4 Intervention phase (Trial) 
Symptoms and lung function assessed during the screening and the first three 
follow-up assessments were analyzed for all 384 subjects designated "probably 
at-risk." Subjects fulfilling the following criteria were invited for a prospective, 
placebo controlled, double blind study with an inhaled corticosteroid during a 
period of one year, as they were considered as being in need of treatment. 
Intervention criteria 
1 Reduced FEV, (less than 2SD of the reference value of FEV,31) during at 
least two of the first four measurements. 
or 
2 PC^-histamine less than 2 mg/ml combined with a reversibility of FEV, 
greater than 15% of the predicted value. 
In total 54 subjects fulfilled the above criteria and were invited to participate in 
the trial. The remaining subjects continued the monitor-phase according to the 
design presented in the previous section (1.3.3). These subjects have not been 
considered for the current thesis. 
During the trial respiratory symptoms and lung function were assessed once 
every three months. Respiratory symptoms were assessed at the surgery of the 
GP while the lung function was assessed at the Department of Pulmonology, 
Dekkerswald. The results have been presented in chapter 4, 5, and 8. 
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2 Prevalence of asthma and COPD in general practice 
in 1992: Has it changed since 1977? 
2.1 Abstract 
Background: Asthma and COPD are common diseases of the airways which are 
mainly diagnosed and treated in general practice. 
Aim: Various studies have reported an increase in the morbidity of asthma and 
COPD. There are two possible reasons for such an increase. The first is an 
apparent increase caused by using different criteria in defining asthma/COPD 
and by increased awareness of the disease by doctors and patients. The second 
is a real increase caused by an increase in the prevalence of airway pathology. 
The aim of this study was to determine the cause of the observed increase in 
morbidity. 
Method: In 1977, a sample of 2328 adults from the general population were 
screened for asthma and COPD. Those screened were then divided into five sub-
groups (grades 1-5), according to severity of: (1) respiratory symptoms; (2) loss 
in FEVV The number of patients who were not known to the general practitioner 
prior to the screening as having asthma or COPD, grades 1-5 were also 
assessed. In 1992, we studied a different sample of 1184 adults of the general 
population in the same area. We used the same criteria as in 1977 to analyze 
our results. The number of patients not known to the general practitioner prior 
to the screening were also studied. 
Results: The overall prevalence (grades 1-5) of asthma and COPD has increased 
from ±19% in 1977 to ± 3 1 % in 1992 (range 21-42). The main reason for this 
is an increase in prevalence of very mild to moderate asthma and COPD (grades 
1-3) from 17% in 1977 to 27% in 1992. The prevalence of severe cases 
(grades 4-5) increased from 2% in 1977 to 4% in 1992. In 1992 around 65% 
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of the patients were not known to the general practitioner as having any grade 
of asthma or COPD. This was only slightly lower than the 72% in 1977. All 
patients with a severe disease (grade 5) were known to the GP. 
Conclusions: There is a real increase in the prevalence of asthma and COPD, 
caused predominantly by an increase in the number of mild cases. The 
percentage of patients not known to the GP were predominantly mild cases. 
2.2 Introduction 
Asthma and COPD are common chronic diseases of the airways that are mainly 
diagnosed and treated in general practice. In the Dutch health-care system, 
every inhabitant is registered at a local general practice. The general practitioner 
(GP) is the provider of basic medical care to an average of 2500 people and is 
the gateway to specialized care. Therefore, it is important that each GP knows 
the population in their practice. 
The prevalence of asthma and COPD in the general population has been 
compared to an iceberg. The visible part of the iceberg represents patients 
known to either the GP or the pulmonologist and specialized asthma centres 
(registered morbidity). The submerged part represents people with respiratory 
symptoms and other objective signs of asthma and COPD who are not known to 
the health-care system but who are detected during screening surveys. Its 
numbers result from underdiagnose1 and under-presentation by the patient. 
This under-presentation may be explained by the absence of a good correlation 
between respiratory symptoms and lung function.2 
Various studies have reported an increase in the morbidity and mortality of 
asthma.э-4Бв This is alarming, especially with the abundance of adequate 
treatment currently available. It is difficult to assess the incidence and 
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prevalence of chronic respiratory diseases.7 The use of various definitions has 
been shown to be a probable cause for this discrepancy in prevalence data.8 
The percentage of patients not known to the GP also varies for the different 
studies and can be assumed to be because of the same reason. Therefore, it is 
important to know whether the increase in prevalence is caused by a real 
increase in the pathology of the airways, or whether it is an apparent increase 
caused by better means of detection or merely reflects a change in diagnostic 
criteria applied. This is summarized in Figure 1. Figure 1A shows the situation 
several years ago, with the tip and the submerged parts of the iceberg 
representing the detected and undetected cases, respectively. Figure 1B 
represents a possible explanation for the increase in morbidity by increased 
awareness on the part of the doctor and patient, or by better methods of 
detection. In this case, a decrease in the percentage of persons not known to 
the GP could be expected owing to an upward shift of the iceberg. Another 
possible explanation for the increase in morbidity is shown in Figure 1С; in this 
case, it results from an overall increase in the prevalence of asthma and COPD. 
Past Present 
Figure 2.1: Possible reasons for the increase in prevalence of asthma and COPD 
in the general population. 
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The aim of this study was to investigate the prevalence of asthma/COPD and 
the percentage of adult patients currently not known to the GP compared with 
that of several years ago. We investigated this by means of a screening survey 
conducted in 1992 and a comparison of the results with a screening survey 
conducted in 1977. The results of the survey in 1992 were analyzed by the 
same criteria used in 1977. 
2.3 Methods 
This study is a comparison between a population survey (screening) for 
asthma/COPD in 1992 and a population survey in 1977, performed in the same 
suburban region of the eastern part of the Netherlands. 
Population survey in 1992: 
In 1992, we screened a sample of the adult population from the sex-age register 
of 10 general practices (city and rural) around the city of Nijmegen, the 
Netherlands, for symptoms and signs of asthma and COPD. This was the initial 
stage of a longitudinal study conducted by the Departments of General Practice 
and Pulmonology of the University of Nijmegen on the early detection, 
monitoring and intervention of asthma and COPD in general practice (DIMCA 
project). The respective GP's were then asked to exclude all persons who 
fulfilled at least one of the five exclusion criteria: congestive heart failure, lung 
disease other than asthma/COPD, serious morbidity with reduced life 
expectancy, or severe physical or mental handicap. Patients with asthma/COPD 
dependent on corticosteroids were also excluded from the screening. This last 
group was further included in the analyses of the present study. All other 
subjects were invited to take part in this survey. Those not responding to the 
first letter were sent a reminder. The screening took place at the office of the 
respective GP and was done by investigators who had undergone prior training 
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in administering questionnaires and testing lung function. All participants gave 
their consent in writing after being fully informed of the study. 
Recruitment-bias: 
In order to investigate the presence of a recruitment bias, a random sample of 
persons who refused to take part in the study were asked to consider taking a 
simplified version of the screening test at their own homes. Most patients 
refused to take part initially because of the use of bronchodilators (medication) 
during the reversibility test and the inconvenience caused by having to visit the 
office of the general practitioner for the screenings test. 
Respiratory symptoms and lung function: 
Symptoms were assessed by means of a modified dutch version of the MRC 
questionnaire.9 
The FEV, was measured by means of a portable Microspiro HI-298 (Chest 
corporation, Tokyo, Japan).10 After sufficient instructions, the subject was 
asked to perform three forced expiratory manoeuvres from maximum inspiration. 
The FEV, corresponding to the manoeuvre with the highest sum of the FEV, and 
FVC was recorded as the FEV, at that moment. 
The degree of reversibility of the airway obstruction: 
The subject was administered 800 |/g salbutamol by inhalation, immediately 
after the base-line measurements. The FEV, was measured again after 15 min. 
The degree of reversibility was defined as the change in FEV, as a percentage of 
the predicted value.11 
Patient characteristics of persons already diagnosed and treated by the general 
practitioner 
We analyzed various patient characteristics, such as age, gender and lung 
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function, of people who had been diagnosed by the GP at the time of the 
screening, and who were using non-steroidal medication for asthma/COPD. The 
patients on steroids (excluded from screening) were not considered for this 
analysis as this medication might have influenced the medical status of these 
patients. We compared the patient characteristics of those using (non-steroidal) 
medication with that of patients not using medication, in order to learn more 
about the type of patient the GP considers in need of medication. 
Comparison with survey in 1977 and analysis: 
A survey by Huygen et al on asthma and COPD, published in 1977, served as a 
comparison.12 This survey included patients above the age of six years 
(n = 4623), registered in one general practice, and followed a two-step 
approach. First, all participants had to complete a five-item questionnaire 
enquiring about shortness of breath, cough and phlegm production, wheezing, 
and asthma attacks. Those with at least one positive answer were invited for a 
follow-up study which consisted of a respiratory symptoms questionnaire9,12 and 
a lung function test (FEV,). All participants were then divided into 6 groups 
(grades 0-5) according to the severity of symptoms and the deficit in FEV,,9 
which were accepted Dutch criteria at that time (Table 2.1). The prevalence of 
the different grades of asthma/COPD were reported along with the rate of cases 
diagnosed before in routine general practice care. 
For the purpose of this study, the data of the 1977 survey were restricted to 
adult subjects between 25 and 70 years of age (n = 2328). The 1992 
questionnaire contained all questions used in 1977. The data were analyzed in 
the same two-step manner as performed in 1977 and expressed in the six 
degrees of severity. All patients in the 1992 sample on maintenance 
corticosteroid treatment were included in the present study and allocated to 
severity degree 5. We compared the prevalence, severity and percentage of 
cases diagnosed in routine general practice care in 1992 and 1977. 
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A summary of the criteria of severity of asthma/COPD used in 1977. The results 
of the 1992 survey were analyzed with the same criteria. 
Severity Symptoms and signs 
Grade 0 Respiratory symptoms absent 
(chronic cough, chronic expectoration, dyspnoea, wheezing, 
asthma attacks, episode of bronchitis) 
and FEV, > 95% predicted value 
Grade 1 At least one of the above symptoms positive 
and FEV, > 95% predicted value 
Grade 2 At least one of the above symptoms positive 
or FEV, 85-95% predicted value 
Grade 3 Symptoms and FEV, > 95% predicted value 
or FEV, < 85% predicted value 
Grade 4 Symptoms and FEV, 75-90% predicted value 
Grade 5 Symptoms and FEV, < 75% predicted value 
Statistical analysis 
The differences between patients using medication (non-corticosteroid) and 
those not using any medication was tested by means of the unpaired Student's 
t-test (normally distributed variables) or by the chi-square test (class variables). 
P-values less than 0.05 were considered significant. The 95% confidence 
intervals were calculated for the prevalence of asthma/COPD for the sample in 
1977 and the 10 samples in 1992. Chi-square tests for proportion were applied 
to compare the prevalence of each sample in 1992 with that in 1977. 
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2.4 Results 
Population survey in 1992: 
One thousand nine hundred and eighty-eight subjects of ages 25 to 70 were 
randomly selected from the 10 practices (Table 2.2). The general practitioners 
excluded 239 (12%) on basis of the exclusion criteria; 29 out of the 239 
subjects were excluded because of the use of inhaled corticosteroids for their 
asthma/COPD. In total, 1749 subjects were invited, of whom 1155 (66%) 
consented to participate in this survey. The 29 patients using inhaled-steroids 
for asthma/COPD were also considered for analysis. They had been excluded 
from screening because steroids are known to alter the normal course of lung 
function and symptoms in patients. These patients had previously been 
diagnosed and treated by the respective GP. Therefore the total study 
population consisted of 1184 subjects. 
Table 2.2 
Number of subjects involved In the surveys In 1977 and 1992. In 1992. 1155 
subjects were screened and 29 were excluded from screening because of the 
use of inhaled corticosteroids. 
Sample size 
Excluded from screening 
Number of persons invited 
Number of participants 
Number of adult participants (age 25-70) 
1992 
1988 
239 
1749 
1184 
1184 
1977 
4623 
0 
4623 
4342 
2328 
Recruitment-bias: 
Thirty-four randomly chosen non-participants were willing to take the simplified 
version of the screening test. Patient characteristics of the non-participants were 
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compared with that of the participants. There were no significant differences 
between the two groups. 
Patient characteristics of persons already diagnosed and treated by the GP: 
There were 58 subjects who were under treatment for asthma/COPD. Twenty-
nine had been excluded from screening on the grounds of corticosteroid 
dependency, and 29 of the total screened were receiving non-steroid treatment 
(Table 2.3). This last group did not differ from the total sample screened in age 
and gender, but had a significantly lower FEV,-predicted (83% versus 97%; 
p<0.001), lower vital capacity, lower FEV, a significantly higher reversibility 
(10% versus 3%; p<0.001). 
Table 2.3 
A comparison of patient characteristics within the 1992 survey: The 1155 
patients screened were considered for this analysis. Patients using medication 
fnon-corticosteroid) at the time of the screening versus the rest. The standard 
deviations have been presented within parentheses. 
Patient characteristics 
Number 
Age (years) 
Sex %(male:female) 
Vital capacity (ml) 
FEV, (ml) 
FEV, % of predicted 
Reversibility 
* = p<0.0S 
Using medication 
29 
43(13) 
38:62 
3644 (823) 
2744 (757) 
83% (17) 
10.1% 
(10.3) 
• 
* 
» 
* 
Rest 
1126 
43(12) 
45:55 
4081 (1054) 
3253 (838) 
97% (14) 
3 .1% (3.7) 
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Prevalence of asthma/COPD in 1992: 
The total prevalence of asthma/COPD (grades 1-5) was 306/1000 screened 
(Table 2.4). The prevalence for each of the 10 practices varied from 210/1000 
to 420/1000 (Table 2.5). Most cases were mild (grades 1 and 2: prevalence of 
203/1000). Moderate cases (grade 3) accounted for 68/1000 and a prevalence 
of 35 was found for severe cases (grade 4 and 5). 
Table 2.4 
The severity and prevalence of asthma/COPD in 1992 compared with 1977. The 
number of cases per grade of severity as a percentage of the total prevalence 
has been presented. The percentage of cases not detected in routine care 
(unknown to GP) is also presented. 
Severity Prevalence 
(per 1000) 
Distribution of cases Unknown to GP 
(% of total (% of prevalence) 
prevalence) 
1992 1977 1992 1977 1992 1977 
Grade 1-2 
Grade 3 
Grade 4-5 
Total (1-5) 
203 
68 
35 
306 
151 
17 
22 
190 
67 
22 
11 
100 
79 
9 
12 
100 
73 
70 
7 
65 
80 
61 
31 
72 
Percentage of persons with asthma/COPD grades 1-5 who were not known to 
the general practitioner in 1992 
Out of the 362 cases identified at the survey, 65% had not been diagnosed 
before in general practice (Table 4). For the mild (grades 1-2) and moderate 
(grade 3) cases, this was 73% and 70%, respectively. Most of the severe cases 
(grade 4 and 5) had already been diagnosed: a first time diagnosis was made in 
only 7%. No new cases with a severity grade 5 were found. 
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Table 2.5 
A comparison of the prevalence in 1977 with that of the 10 separate samples 
(95%CI) and the aggregated total in 1992. The prevalence (practices) and the 
95% CI (presented as a percentage) are given for each sample. The results of 
the chi-squared test for comparing the prevalence in 1977 versus each sample 
in 1992 are shown in far-right column. 
Sample No. of No. cases Prevalence 95% CI Comparison of 
subjects found (%) proportions 
screened (p-value) 
1977 
1992: 1 
1992: 2 
1992: 3 
1992: 4 
1992: 5 
1992: 6 
1992: 7 
1992: 8 
1992: 9 
1992:10 
1992: 1-10 
2328 
215 
111 
127 
114 
89 
100 
106 
109 
107 
106 
1184 
443 
60 
31 
40 
38 
34 
21 
25 
33 
45 
35 
362 
19.0 
27.9 
27.9 
31.5 
33.3 
38.2 
21.0 
23.6 
30.3 
42.0 
33.0 
30.6 
17-21 
22-34 
19-36 
23-40 
25-42 
28-49 
13-29 
15-32 
21-39 
33-52 
24-42 
28-33 
-
0.002 
0.019 
0.001 
0.002 
0.000 
0.610 
0.239 
0.004 
0.000 
0.000 
0.000 
Comparison of 1992 and 1977 
The total prevalence of asthma/COPD in 1992 was substantially higher than in 
1977 (306/1000 versus 190/1000). Table 2.5 shows that eight of the 10 
practices screened in 1992 had a significantly higher prevalence than the 
practice in 1977. The main reason for this increase in prevalence is an Increase 
In mild to moderate forms of asthma and COPD (grades 1-3). The prevalence of 
grades 1-3 has increased from 168/1000 in 1977 to 271/1000 in 1992 (Table 
2.4). Out of the 362 cases identified in the 1992 survey, 35% had previously 
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been diagnosed in routine general practice compared with only 28% of the 
cases in 1977. This was particularly true for the most severe cases (93% versus 
69%). 
2.5 Discussion 
In this study, we compared the results of a population survey on asthma and 
COPD, conducted in 10 general practices in 1992, with the results of a survey 
in one practice in 1977. This study indicates an increase in the prevalence of 
asthma/COPD from 1977 to 1992. The main reason for this is an increase in 
prevalence of mild to moderate asthma and COPD (grades 1-3). A substantial 
number of cases found during the survey had not been picked-up in routine 
patient care. In 1992 and in 1977, most of the more severe cases had already 
been detected. There is a trend towards greater detection in recent years 
(especially of the more severe cases), and this may point to greater asthma (and 
COPD) awareness. 
For all ages, population surveys have reported a prevalence of 10-30%1,13. In 
general practice morbidity registration, prevalence of 30/1000 are consistently 
given14,15·16. This same discrepancy between cases present in the 
population (screening) and identified in routine general practice care (presented 
morbidity) came forward from this study. 
The prevalence of asthma and COPD are influenced by the age and gender of 
the population, cigarette smoking, social class, urbanization, and probably the 
level of air pollution. These factors will have influenced the comparison made in 
this study. The surveys of 1977 and 1992 were held under comparable 
conditions in the same suburban region of the east of the Netherlands. The 
majority of patients in both surveys were from working class. The patients in 
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1992 had been recruited from practices other than the one involved in the 1977 
survey, and therefore, the 1977 results will not have influenced the awareness 
of their general practitioner of undetected asthma/COPD. Selective participation 
could not be demonstrated in the 1992 survey, and in 1977, the complete 
practice population of one general practice had been invited for participation, of 
whom 9 0 % completed both stages of the survey. What could not be controlled 
for was the influence of active (and passive) smoking. It is likely that the 
national trend for a modest reduction in smoking in the past decade will also 
have been applicable to this region. Conversely, the levels of air pollution 
(motorized traffic and industrialization) have increased since 1977. In comparing 
morbidity between general practices it is important to take into account practice 
routines, as these may be a source of bias of reported/registered morbidity. A 
comparison of proportions (prevalence) between the practice in 1977, and the 
10 practices in 1992 separately, shows that eight practices had a significantly 
higher prevalence than in 1977. Five percent of the practices could be expected 
to differ significantly because of chance. In our study, 80% of the practices 
differed significantly from that in 1977; therefore, it is highly unlikely that this 
increase was caused by chance. This study was based on practices affiliated 
with the Department of General Practice, University of Nijmegen. The practice 
involved in the 1977 survey played a predominant role in morbidity registration 
since 1967, and had developed a routine in the diagnostic labelling of presented 
morbidity at the time of the 1977 survey. This probably will have facilitated the 
diagnosis of asthma/COPD. Therefore, the percentage of patients unknown was 
probably lower than in the average general practice of 1977. The practices of 
the 1992 survey were practices of the Department of General Practice in 
Nijmegen. These practices had been previously involved in a series of studies on 
asthma and COPD with special emphasis on early diagnosis and long term 
follow-up.1017 Again, this will probably have enhanced the number of cases of 
asthma/COPD under care. Although it is important to be cautious in comparing 
morbidity rates between different practices, our data represent, in our opinion an 
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optimum in this respect; the information of patients diagnosed with 
asthma/COPD in supervised 'academic' general practice in 1977 and 1992. The 
1992 survey was held outside the practice area involved in the 1977 survey, 
and therefore, the results were not directly influenced by the 1977 survey. 
However, as it was performed in the same region of the country, in our view, it 
is correct to compare these data and to conclude a trend towards an increased 
prevalence of asthma/COPD with, at the same time, a somewhat higher 
proportion of cases already detected in routine patient care. 
Our study shows that the 'iceberg' of asthma/COPD consists mainly of patients 
with mild symptoms. However, there are some patients with undetected 
symptoms and/or lung function deficits (grades 3-4). The patients under 
maintenance treatment with inhaled corticosteroids were included in the 
analysis. However, it was not possible to assess the severity of the disease in 
these patients as the corticosteroid treatment will have influenced signs, 
symptoms and spirometrie performance. Therefore, these patients were 
excluded from the initial screening. Inclusion of these patients, in the most 
severe grade of disease was, in our perception justified, but arbitrary. It was 
reassuring that no new patients with a serious form of the disease (grade 5) 
were identified during screening: thus, all severe cases were positioned in the 
tip of the iceberg. More attention should be paid to patients of mild and 
moderate severity. Our study did not address the question why cases detected 
at screening had not been diagnosed before in routine general practice care. It is 
important to stress the fact that this is a controversial point: there is no 
evidence available to this group that early and preventive care will improve the 
long term outcome of the disease - evidence that is already available for more 
severe grades of asthma/COPD17. As a consequence of this, there is no 
scientific basis to promote early presentation, detection and treatment of mild 
cases. It is our objective to pursue this question in the follow-up of this study: 
all patients who are found to be in need of treatment will be invited for a 
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randomized, double blind, placebo controlled trial to study the effectiveness of 
inhaled corticosteroids for such patients detected by means of a screening 
survey. 
One of the reported reasons for underpresentation of asthma is that people get 
accustomed to symptoms and do not find it necessary to consult the general 
practitioner17. In that particular case, the general practitioners cannot be blamed 
for the fact that a high percentage of patients remain unknown to them. 
However, it is very important that patients who do consult the general 
practitioner for their symptoms are diagnosed and properly treated. From our 
data, it can be inferred that general practitioners are more aware of 
asthma/COPD: a higher proportion of severe cases had been detected in 1992 
compared to 1977. Our contacts with the subjects during screening gave a 
strong suggestion that those with respiratory abnormalities had only seldom 
consulted their general practitioner for these problems, indicating under-
reporting of symptoms. The subjects already under treatment had significant but 
mild spirometrie abnormalities. 
We can conclude that there is a real increase in the prevalence of asthma and 
COPD. Of these patients, nearly all of the most severe cases have been 
diagnosed in routine patient care. Less severe cases form the majority of 
patients, and despite an over-all increase of cases identified in daily (general) 
practice care, the percentage not known to the GP still has remained high. 
Greater insight is mandatory for effective early intervention in this group before 
sound recommendations can be made to improve early diagnosis of these 
patients. 
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3 Underpresentation of asthma in general practice. Is it 
caused by poorly perceived dyspnoea or by psychological 
factors? 
3.1 Abstract 
Background: It is important to diagnose patients with obstructive airways 
disease (OAD) such as asthma and COPD at an early stage, as proper treatment 
of such patients may improve their prognosis in the long run. However, in many 
cases, patients do not see the need to consult their GP for respiratory symptoms 
at an early stage. 
The aim of study: To investigate the magnitude of underpresentation of 
respiratory symptoms in a random sample of the general population and to 
assess the influence of perception of shortness of breath and psychological 
factors on whether a patient would consult the GP for shortness of breath. 
Method: A random sample of 1155 adults in the general population were 
screened for respiratory symptoms (questionnaire) and lung function. A 
subgroup of 147 subjects with shortness of breath were tested for their ability 
to perceive this by means of a Borg score during a histamine challenge test. The 
psychological profile of a sample of 130 subjects was assessed by means of five 
validated questionnaires, namely; the Utrecht Coping List, the State-Trait 
Anxiety Inventory, the Multidimensional Health Locus of Control Scale, the 
Respiratory Illness Opinion Survey and the Dutch Personality Inventory. 
Results: Of the 1155 adults screened, 439 had at some stage experienced 
shortness of breath. Of these subjects only 28% had ever consulted their GP for 
this. Almost twice as many subjects with a good perception consulted the GP in 
comparison to those with a poor perception (34 versus 18%, O.R.: 2.3, 95% 
C.I.: 0.8-6.6). Psychological factors had no significant influence on the patient's 
choice to consult the GP for shortness of breath. 
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Conclusions: We conclude that on the basis of these results it seems that 
underreporting of symptoms is a major factor contributing to underdiagnosis of 
asthma in the population. This seems to be caused by a decreased perception of 
dyspnoea and not by psychological factors. Increased public awareness of the 
consequences of seemingly mild symptoms should be carefully propagated, 
specially to subjects who perceive shortness of breath, if underpresentation of 
symptoms is to be reduced or eliminated. This would provide the general 
practitioner the opportunity for better diagnosis and treatment of patients with 
asthma at an early stage. 
3.2 Introduction 
Various studies have shown an increase in morbidity and mortality of 
asthma.1,2·3 This increase might be due to underdiagnosis and eventual 
undertreatment of this disorder.4 The general practitioner (GP) has often been 
blamed for the underdiagnosis of asthma as the GP represents the front line in 
medical care.6 This has been illustrated by the fact that most population surveys 
on asthma report a prevalence of approximately 100 per 1000 subjects 
screened,8,7 in contrast to a prevalence of 10 per 1000 which is consistently 
reported in morbidity registration systems of general practice.βθ This would 
indicate that only ten percent of the subjects with asthma are diagnosed as such 
by their GP's. However, this observation does not exclusively point to 
underdiagnosis by the GP as the discrepancy may also be caused by 
underpresentation of respiratory symptoms by the patient.10 It is therefore 
important to quantify the level of underpresentation and to investigate why 
patients do not present their symptoms to the GP. Respiratory symptoms do not 
correlate well with objective measures of airflow obstruction and patients with 
only a few (mild) symptoms could have a serious deficit in forced expiratory 
volume in one second (FEV,).11 In addition, it has been suggested that 
underpresentation may be caused by poor perception of asthma.12 Shortness of 
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breath is in our opinion the core alarm symptom in asthma depicting airways 
obstruction which triggers the patient to consult the GP. This might be less for 
symptoms such as cough and phlegm production which are experienced more 
often and may be associated with innocent conditions as a common cold. From 
this it can be inferred that (lack of) perception of shortness of breath can be an 
important factor leading to undertreatment of asthma.13·14 Psychological factors 
such as coping behaviour, attitude, anxiety and neuroticism may also play a role 
in symptom perception and in the patients' decision to consult the GP. Patients 
with a good perception of shortness of breath may still be reluctant to consult 
the GP because of several psychological features. 
The aim of this study was to investigate the magnitude of underpresentation of 
shortness of breath to the GP in subjects with signs and symptoms of asthma, 
and to assess the influence of perception of shortness of breath and 
psychological factors on consulting the GP. It was part of a larger study on the 
screening of asthma in the general population.10 
3.3 Methods 
Design: 
This study was based on a screening for asthma in a random sample of adult 
subjects who were recruited from the practice registers of ten general practices 
in the Nijmegen region.10 During this screening we assessed whether the 
participants had ever experienced shortness of breath in the past and whether 
they had ever consulted their general practitioner or chest physician for this. This 
was done by means of a respiratory symptoms questionnaire. Patients detected 
with signs and symptoms of asthma during the screening were invited for a 
follow-up study. The ability to perceive shortness of breath was assessed in 147 
consecutive patients who visited the lung function laboratory for a histamine 
challenge test during a given period of three months within the follow-up phase. 
This inclusion period was limited to three months due to logistical reasons. 
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During this period 130 of these subjects were administered the psychological 
questionnaires at their homes. 
Patients 
Details of the selection process was described in detail elsewhere:10 In 1992 a 
random 10% sample of subjects between 25 and 70 years of age were selected 
from practice registers of ten general practices (city and rural) around the city of 
Nijmegen (η = 1988). The general practitioner excluded all patients with (a) 
congestive heart failure; (b) lung disease other than asthma/COPD; (c) any other 
serious morbidity with reduced life expectancy; (d) severe physical or mental 
handicap, and (e) patients with asthma/COPD dependent on inhaled or oral 
corticosteroids. This last category was excluded because steroids are known to 
influence bronchial symptoms, bronchial hyperresponsiveness and possibly also 
the perception of dyspnoea.1216 In total 239 (12%) were excluded on the basis 
of these five criteria of which 29 were steroid-dependent. The remaining 1749 
subjects were invited for the screening, of whom 1155 (66%) participated. A 
comparison of patient characteristics of participants and non-participants 
revealed no recruitment bias during the selection procedure.10 All participants 
gave their consent in writing after being fully informed of the study. The study 
was approved by the Medical Ethics Committee of the University of Nijmegen. 
The screening consisted of a standardized respiratory symptoms questionnaire 
including a question on whether the subject had ever consulted the GP or chest 
physician for shortness of breath in the past. Subjects with one or more of the 
following criteria were considered to have signs and symptoms of asthma and 
were invited for the follow-up phase of the study: 
presence of dyspnoea, coughing, phlegm production or wheezing during at 
least three months in the preceding year, and/or: 
bronchial obstruction defined as FEV, <, predicted value minus 1.64 
standard deviation 
the reversibility after the administration of 800 μ$ salbutamol 2: 15 % of 
predicted value. 
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Respiratory symptoms and lung function assessed during screening 
Symptoms were assessed by means of a modified Dutch version of the MRC 
questionnaire.1 6 The FEV1 was measured by using the portable Microspiro Hl-
298 (Chest corporation, Tokyo, Japan).1 7 After sufficient instructions the 
subject was asked to perform three forced expiratory manoeuvres from 
maximum inspiration. The FEV, corresponding to the manoeuvre with the highest 
sum of the FEV, and FVC was recorded as the FEV, at that moment. The subject 
was administered 800 μQ salbutamol by inhalation, immediately after the base­
line measurements. The FEV, was measured again after 15 minutes. The degree 
of reversibility was defined as the change in FEV, as a percentage of the 
predicted value.1 8 Respiratory symptoms and lung function were assessed for 
each participant during the screening by investigators who had undergone prior 
training in administering questionnaires and in spirometry. 
Allergy 
The presence of allergy was assessed by skin tests for 16 common inhalation 
allergens (Pharmacia Sweden: Pollen, weeds, grasses, trees; Animals: cats, 
dogs, rabbits, guinea-pig, sheep; house dust mite; Aspergillus fumigates). 
Patients were considered allergic if at least one skin test was positive. 
Histamine provocation test and the experienced level of shortness of breath. 
The PC^-histamine was assessed in the lung function laboratory according to 
the method described by Cockcroft.1 9 Patients with a base-line FEV, less than 1 
litre, or less than 5 0 % of the predicted value were not subjected to histamine 
provocation. Aerosols of histamine were administered in doubling concentrations 
from 0.03 mg/ml up to 32 mg/ml at five-minute intervals. Inhalation was stopped 
when a fall in FEV, of 2 0 % from the base-line value was recorded. Patients were 
instructed to record their experienced level of shortness of breath thirty seconds 
after each administered dose of histamine and immediately prior to the FEV, 
measurement. The magnitude of experienced shortness of breath was rated by 
choosing a verbal descriptor on a vertical oriented modified Borg scale. The Borg 
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scale is a 12-point ordinal scale ranging from 0 (" no breathlessness at all") and 
0.5 ("very, very slight breathlessness") to 10 ("maximum breathlessness").14 
Psychological characteristics 
The following five validated self-administered questionnaires were used for this 
purpose: 
1 The Utrecht Coping List (UCL): assesses coping behaviour, where coping is 
defined as "constantly changing cognitive and behaviourial efforts to manage 
specific external and/or internal demands that are appraised as taxing or 
exceeding the resources of the person".20 The UCL contains 47 items which 
make up seven scales: Active tackling. Palliative responses. Avoidance, 
Seeking social support. Depressive responses, Expressing emotions and 
Comforting cognitions. In the current study only the first four scales were 
used. 
2 The State-Trait Anxiety Inventory: assesses state anxiety and trait anxiety 
with 20 items per sub-scale.21 This study assessed the state anxiety (extent 
of anxiety the patient feels when being short of breath). 
3 Multidimensional Health Locus of Control Scale: assesses perceived causes 
of health and illness.22 It has three sub-scales: 'internal' (health and illness 
are the consequences of one's behaviour), 'external' (health and illness are 
the consequences of factors outside one's control, e.g., the physician, God) 
, and 'chance' (health and illness are consequences of chance). 
4 The Respiratory Illness Opinion Survey: assesses attitudes of patients with 
respiratory disorders towards their illness.23 In the current study the two sub-
scales Optimism (reflecting the extent of optimism of the patient concerning 
the future of the illness) and Stigma (reflecting the extent to which the 
patient feels stigmatised because of the illness) were used. 
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5 The Dutch Personality Inventory: assesses seven personality traits with 133 
items. In the current study only the sub-scale Inadequacy (or 'neuroticism') 
was measured in a self-administered format.24 
Analysis 
The frequency of experienced shortness of breath was taken from the screening 
questionnaire, and it was computed to what extent a doctor had been consulted 
for it in the past. Perception of shortness of breath was assessed by means of a 
BORG-score. The change in FEV, and the corresponding BORG-score was 
calculated for at least four histamine dosage steps of the challenge test by 
means of regression analysis.14 Subjects who reached a 20% decline in FEV, in 
less than four doubling-dosage steps during the histamine challenge test had to 
be excluded from this analysis, as regression coefficients were not reliable. 
Patients were classified in three groups: (1) "no shortness of breath" if no 
apparent decrease in FEV, during the histamine challenge test was observed; (2) 
"good perceivers" if a decline in FEV, and a simultaneous increase in the BORG 
score was observed; (3) "poor perceivers" if a 20% decline in FEV, was not 
accompanied by any increase in the BORG score. 
The five psychological characteristics were calculated from the questionnaire 
scores. The frequency of consulting a doctor for shortness of breath was 
computed for "good perceivers" and "poor perceivers", and was related to the 
observed psychological characteristics. In a logistic regression analysis the 
influence of perception on the consultation to the GP (corrected for age, sex, 
smoking behaviour, hyperresponsiveness, allergy and lung function) was 
investigated. 
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3.4 Results 
1) The magnitude of under-presentation 
First we investigated the relationship between having experienced shortness of 
breath at some stage in the past and consulting the GP for this. 439 of the 1155 
randomly screened subjects had experienced shortness of breath at some time in 
the past of which only 123 (28%) had consulted the GP for respiratory 
symptoms. 
2) Perception of shortness of breath 
The ability to perceive shortness of breath was assessed in 147 consecutive 
patients during the histamine challenge test. All had experienced shortness of 
breath in the past. In total 12 subjects, were excluded from analysis because 
they had less than the minimum of four doubling-dose steps of histamine. The 
remaining 135 subjects had more than four doubling-dose steps during the 
histamine provocation test and were considered for analysis. Of these 135 
subjects, 107 were classified as having a "good perception" of shortness of 
breath and 28 as having a "poor perception". Good perceivers of shortness of 
breath could be discriminated from poor perceivers as the former had a higher 
level of bronchial hyperresponsiveness, a lower lung function and a were more 
allergic (Table 1). Of the 107 subjects with a good perception 34% had 
consulted the GP prior to the screening compared with only 18% of the poor 
perceivers (n = 28). (o.r.: 2.3, 95% ci. : 0.8-6.6). 
3) Psychological characteristics 
In total 130 subjects who had experienced shortness of breath in the past 
answered the five psychological questionnaires. Twenty seven had consulted the 
GP in the past for shortness of breath, and 103 had never consulted the GP for 
shortness of breath. None of the psychological factors tested, showed a 
significant difference between the two groups (Table 3). 
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Table 3.1: 
A comparison of the clinical characteristics between the good perceivers and 
the poor perceivers f η = 135). Standard deviations are shown within 
parenthesis. 
Good perception Poor perception 
Number 
Sex (M/F) 
Age (years) 
Allergy { + /-) 
Log PC20 
FEV, (ml) 
FEV, (% 
predicted) 
Reversibility (%) 
Pack years 
( · p < 0 . 0 5 ) . 
107 
40/67 
43 (12) 
44/63 
2.5 (2.7) 
3068 (725) 
9 3 % (14.4) 
5.5 (5.0) 
8.2 (10) 
28 
14/14 
46 (11) 
5/23 
4.5 (1.3) 
3338 (683) 
1 0 1 % (16.1) 
4.4 (3.6) 
8.0(10.7) 
Table 3.2: 
The relation between perception of shortness of breath and consultation of the 
GP for shortness of breath. 
+ 
Perception of 
shortness of breath 
— 
Consul 
+ 
36 (34%) 
5 (18%) 
41 
tation of GP 
— 
71 (66%) 
23 (81%) 
94 
107 
28 
135 
4 6 
Chapter 3 
Table 3.3: 
Psychological characteristics of 130 patients (good and poor perceivers of 
dyspnoea) who consulted the GP for bronchial symptoms and who did not 
consult the GP in the past. Standard deviations have been presented within 
brackets. 
Number 
Active tackling 
Avoidance 
Palliative responses 
Social support 
Trait anxiety 
Loc. of cont. internal 
Loc. of cont. external 
Loc. of cont. chance 
Optimism 
Stigma 
Neuroticism 
Consulted GP 
27 
17.3(3.2) 
15.3(3.2) 
10.1 (2.7) 
6.3 (2.3) 
16.3 (4.8) 
14.4 (4.1) 
15.5 (4.5) 
16.5 (4.6) 
19.6 (3.5) 
11.5 (5.6) 
29.4(9.1) 
Did not consult GP 
103 
18.2(3.5) 
15.6(3.2) 
10.8 (2.4) 
6.6 (1.7) 
15.3 (4.7) 
13.8 (4.4) 
14.8 (4.6) 
15.4 (4.1) 
20.6 (3.1) 
12.0 (6.4) 
27.4 (6.3) 
3.5 Discussion 
Our study was based on patients with signs/symptoms of asthma, of whom a 
large proportion indicated that they had experienced shortness of breath in the 
past. However, less than one third of these patients had consulted a doctor (GP 
or chest physician) prior to the screening. A series of consecutive patients tested 
for bronchial hyperresponsiveness under laboratory conditions, indicated to be 
able to perceive shortness of breath. A higher percentage of patients who were 
able to perceive shortness of breath adequately had consulted a doctor, 
compared to those with a poor perception. Patients were further tested for 
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psychological characteristics, in order to identify a specific psychological profile 
that could explain a tendency for consulting a doctor. A range of common 
characteristics was included. However, we found no difference in psychological 
factors between patients with a good perception and those with a poor 
perception. No psychological factors had a significant predictive value on 
whether or not a patient had consulted the GP. 
In recent years more attention has been paid to finding means of preventing 
underdiagnosis of asthma and COPD. Underdiagnosis is an important bottleneck 
in initiating treatment. The development of guidelines on diagnosis and therapy 
of asthma are examples of efforts to address this point. This is particularly 
important since there is evidence that the irreversible loss in lung function can be 
minimized by initiating proper treatment at an early stage.15,25 This leads to the 
issue of symptom perception as a relevant factor in consulting the GP, as it can 
be impaired in some individuals12'14. What is not perceived cannot be presented 
to the GP, and in our view shortness of breath was the most obvious alarming 
symptom of asthma. Though most patients detected with signs and symptoms 
of asthma/COPD on screening, had experienced shortness of breath, most of 
them had not consulted a doctor for it. This was clearly more prominent in 
patients with problems to perceive shortness of breath. 
Several methodological aspects of the study should be given further 
consideration. During the screening we detected patients with signs of asthma 
although they had not previously consulted the GP.10 The severity of asthma in 
some of them was not particularly mild, and therefore causes a problem for daily 
patient care.10 The GP related factors have not been taken into account in this 
design, but the patients were recruited from practices with a special interest in 
asthma. The perception of shortness of breath is a volatile aspect to measure. 
The method applied relied on a laboratory setting, which could be a setting quite 
different from real life. The 'face-validity' of the testing might be challenged, 
though the methodology was developed and applied successfully in other 
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studies.14 Nevertheless the method of assessing perception could have 
influenced these findings. 
Another finding in our study is that patients with a good perception of shortness 
of breath have a lower baseline level of FEV, after correction for age and gender 
compared to the poor perceivers. It seems logical that patients with a lower 
baseline level of lung function perceive it's fluctuations better than those with a 
larger reserve in lung function. This study also shows that patients with an 
allergy or a high bronchial responsiveness have a better perception of dyspnoea 
than others. Brand et al have also reported similar findings.14 In this case it is 
also logical that patients with hyperreactive airways are able to perceive the 
feeling of shortness of breath better than those with normal airways. 
It is important to identify patients with a poor perception of shortness of breath. 
Objective lung function measurements should be made regularly to evaluate the 
presence of bronchoconstriction in such patients. Screening the population for 
such patients is a theoretical possibility. Patients with risk factors could be then 
kept under surveillance. Increased public awareness on seemingly innocent 
symptoms could also help detect patients. The importance of objective 
measurements such as spirometry even in persons with mild symptoms should 
be propagated. However caution must be taken in propagating such information 
to prevent worry and eventual medicalization of the general population. Even a 
screening diagnosis of asthma must rely on the reporting - and therefore the 
perception - of persistent respiratory symptoms by patients. It is also important 
to know why patients who have the capability of perceiving shortness of breath 
do not consult the GP. Is it because of lack of knowledge regarding asthma and 
COPD? In this case careful propagation of information regarding the 
consequences of seemingly innocent symptoms may be useful. Again care 
should be taken not to cause any unwarranted panic in the general population. 
It can be concluded that perception of shortness of breath is not a straight-
forward matter. Our study showed that poor perception is probably a major 
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factor in underpresentation and underdiagnosis of asthma. As shortness of 
breath is a core symptom of early diagnosis, our study may indicate that the 
issue of sufficient importance to warrant further research. 
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4 The early detection of obstructive airways disease by 
means of screening the general adult population 
4.1 Abstract 
Background: Although obstructive airways disease (OAD) is mainly diagnosed 
and treated in general practice there are indications of unregistered morbidity. 
An active policy by GP's pertaining to the early detection of cases in the general 
population needs further investigation. 
Method: A random sample of 1155 subjects from the adult general population 
was screened for respiratory symptoms and lung function. Those designated as 
having probable risk factors for OAD (such as respiratory symptoms, reduced 
FEV, or increased reversibility) and a random sample of healthy controls were 
followed during a period of two years. Respiratory symptoms and FEV, were 
assessed once every three months. Subjects with a reduced FEV, (less than 
2SD of the reference value) on at least two occasions were considered as 
having a persistently low lung function. Subjects with a decline in FEV, greater 
than 80 ml/year at the end of the first year were considered as having a rapid 
decline in lung function. 
Results: We detected 48 subjects (6.9% of the sample screened) with a 
persistently low lung function in the group designated as probably having risk 
factors, of whom 15 (31%) had consulted the GP prior to the screening for 
airways related complaints. None of the controls had a persistently low lung 
function. The positive and negative predictive value of the screening test for 
detecting subjects with a persistently low FEV, was respectively 12.5% and 
100% The positive and negative predictive value of the screening test for 
detecting a rapid decline in lung function was respectively 46% and 61%. 
Conclusions: It is possible to detect subjects with mild OAD by screening the 
general population for respiratory symptoms and lung function. In subjects with 
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a negative screening result a persistently low lung function was absent even 
after repeated assessments (the number of false negatives amounted to zero). 
However, the test is not effective in distinguishing subjects with a rapid decline 
from those with a normal decline. 
4 .2 Introduction 
Diseases caused by airways obstruction such as asthma and COPD are mainly 
diagnosed and treated by general practitioners (GP's). However, the registered 
morbidity in general practice is usually lower than the prevalence reported in 
population surveys.1'23,4 This indicates unregistered morbidity (morbidity not 
registered in general practice) regarding obstructive airways disease (OAD), 
which is probably due to underpresentation by the patient6 and underdiagnosis 
by doctors.8 Guidelines on diagnosis and treatment of asthma78·9'10-11 and 
COPD11-12-13'14·16 have been partly aimed at preventing this underdiagnosis 
and consequent delays in treatment. However, these measures are only 
effective within the registered morbidity, i.e. in patients who have already been 
diagnosed as such. Respiratory symptoms (cough, sputum production, 
continuous or recurrent episodes of shortness of breath and wheeze) may exist 
subclinical^ or may even be consciously ignored by the patient as a temporary 
inconvenience, until progression of the disease may eventually result in 
consulting the GP. It has been reported that most patients do not present with 
symptoms until the lung function is less than 50% of the reference value.15 
Active methods of detection such as screening the general population would 
probably enable the proper treatment of mild patients at an early stage. This 
paper is concerned with the efficacy of a screening procedure with regard to 
early detection. 
Proper treatment at an early stage of the disease may not only reduce morbidity 
but may also improve the long-term prognosis of these patients. However, the 
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main criterion for the diagnosis of asthma or COPD is the presentation of 
respiratory symptoms to the doctor. It has been demonstrated that respiratory 
symptoms even when persistent correlate poorly with spirometry.1" This 
implies that the assessment of respiratory symptoms alone has insufficient 
sensitivity and specificity in detecting patients with OAD. Spirometry should 
also be considered in this respect. The FEV, is seen as the most reliable 
parameter for evaluating lung function. The annual rate of decline in FEV, is 
generally greater in asthma and COPD than under physiological 
conditions17·18'1®. It is the most important index for assessing severity, 
progression and predicting mortality in asthma and COPD.20 The Fletcher 
model18 postulates a certain rate of decline in FEV, after adolescence. 
Thresholds for disability and death have been incorporated in this model. This 
means that subjects with a reduced level of FEV, or with a rapid decline are at 
risk of reaching this threshold at a relatively early stage. 
The aim of this study was to assess the efficacy of detecting subjects in the 
general population with either a persistently reduced level of FEV, or a rapid 
decline in FEV, at an early stage by means of screening. 
4.3 Methods 
Design: In this longitudinal, prospective study, a sample of the adult general 
population was screened for respiratory symptoms, level of FEV, and percentage 
reversibility. Subjects fulfilling at least one of the four screening criteria (see 
paragraph 1.1) were categorized as being "probably at-risk" for OAD. The 
remaining subjects were designated "not at-risk" or healthy. A specific diagnosis 
of asthma or COPD was not made as there was insufficient evidence at this 
early stage to do so. All subjects designated as probably at-risk were considered 
for a follow-up study of two years, for comparison a control group comprising of 
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a random sample of those designated as not at-risk was also invited in order to 
validate the screening criteria. Respiratory symptoms, FEV, and %reversibility 
were assessed once every three months. Subjects who fulfilled one of the two 
criteria for intervention (see paragraph 2.1) during the first year of the follow up 
were withdrawn from the study in order to enable treatment. All participants 
gave written consent after being fully informed of the study. This study was 
approved by the Medical Ethics Committee of the University of Nijmegen. 
Subjects: A sample of 1988 adults between the ages 25 and 70 were invited to 
participate in this study. Subjects were randomly selected from the practice 
registers of 10 general practices around Nijmegen. The general practitioners 
(GP's) were asked to exclude all subjects with a serious disability or life 
threatening disease or those dependent on inhaled corticosteroids. The latter 
were excluded from this study as they had already been diagnosed as having a 
respiratory problem and as both respiratory symptoms and lung function are 
known to be influenced by these drugs. In total 239 subjects were excluded of 
which 29 on the basis of steroid dependency. The remaining 1749 subjects 
were invited, 1155 volunteered to participate while 594 subjects either refused 
to take part or did not respond to our invitation. There was no recruitment-bias 
between participants and non-participants.21 
1. The Screening 
The screening took place at the surgery of the GP and was performed by 
medical doctors who had undergone prior training in administering 
questionnaires and spirometry. 
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1.1 Screening criteria: 
Persons fulfilling at least one of the following four criteria were designated as 
being at-risk. 
1 At least one positive response to the five questionnaire items shown in 
Table 1A. 
2 Measured FEV, < reference value minus 1.64 standard deviation (SD). 
3 Reversibility of FEV, after administering 800 pg salbutamol > 1 5 % of the 
reference value. 
4 At least two of the following three items positive. 
i) At least one positive response to the 12 questionnaire items shown 
in Table 1B. 
ii) Measured FEV, < reference value minus 1.0 SD. 
iii) Reversibility of FEV, between 10 and 15% of the reference value. 
Table-4.1: 
Respiratory symptoms investigated by means of questionnaire 
1_A 
a) Wheeze? 
b) Shortness of breath at rest? 
c) Cough on most days of three months? 
d) asthma? 
e) Respiratory symptoms (cough, wheeze, shortness of breath) caused by: 
animal danders?, household gases and vapours?, exertion?, exhaust 
fumes?, cold air, mist, smog?, cigarette smoke? 
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1_B 
a) Wheeze, wheeze and shortness of breath, wheeze during periods 
without common cold? 
b) Shortness of breath: at rest, awakened by shortness of breath? 
c) Cough: in the morning, during the day, most days of three months? 
d) Phlegm: in the morning, during the day, most days of three months? 
e) Complaints on breathing: continuous, repeated? 
f) Complaints on breathing: when hurrying on flat ground, when walking 
slowly, do you need to rest when walking slowly on flat ground? 
g) Asthma: diagnosed by doctor, during the last 12 months, any asthma 
medication? 
h) Medical history: bronchitis or pneumonia or eczema as child, take part 
in daily activities as child, ever consulted a GP or chest physician for 
wheeze or shortness of breath? 
i) Use of medication: adrenergic agonists, anticholinergics, 
corticosteroids, cromoglycates, theophylline dérivâtes, antihistamines? 
j) Respiratory symptoms (cough, wheeze, shortness of breath) caused by: 
animal danders, house dust, pollen? 
k) Respiratory symptoms during certain seasons? 
I) Respiratory symptoms (cough, wheeze, shortness of breath) caused by: 
household gases and vapours?, exertion?, exhaust fumes?, cold air, 
mist, smog?, cigarette smoke? 
Respiratory symptoms: 
Symptoms were assessed by means of a modified Dutch version of the MRC 
questionnaire.22 The number of symptoms present during the past year was 
scored on a scale of 0-7 depending on the presence of following seven items, a) 
Cough during most days of three months, b) Phlegm production during most 
days of three months, c) Shortness of breath while hurrying on flat ground, d) 
Respiratory symptoms (cough, wheeze, shortness of breath) caused by cold air, 
mist, smog, e) Wheezing during the last 12 months, f) Asthma attack during the 
last 12 months, g) Respiratory symptoms (cough, wheeze, shortness of breath) 
caused by: animal danders, house dust, pollen. 
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Smoking history 
Smoking was quantified by calculating the number of pack years. 25 cigarettes 
per day per year was defined as one pack year. 
FEV, 
FEV, was measured by means of a portable Microspiro HI-298 (Chest 
corporation, Tokyo, Japan)23. After instructions the subject was asked to 
perform three forced expiratory manoeuvres from total lung capacity. The FEV, 
corresponding to the manoeuvre with the highest sum of FEV, and forced vital 
capacity was recorded as the FEV, at that moment. FEV, as a percentage of the 
reference value (standardised for age, height and gender)24 was considered for 
analysis. 
The degree of reversibility of the airway obstruction: 
The subject was administered 800 /yg salbutamol (dose aerosol) by inhalation, 
immediately after the base-line measurements. FEV, was measured again after 
15 minutes. The degree of reversibility was defined as the change in FEV, as a 
percentage of the reference value24. 
2. The follow-up 
Respiratory symptoms and FEV, were assessed once every three months during 
a period of two years, leading in total up to nine assessments. Subjects 
designated as probably at-risk visited the Department of Pulmonology, 
Dekkerswald, once every year (visits 1,5,9) and were assessed by lung function 
technicians during each visit. Quarterly assessments (visits 2,3,4,6,7 and 8) 
were conducted at the surgery of the GP by specially trained practice assistants. 
Subjects designated as not at risk were visited once every three months at their 
homes (visits 1-9) by the medical doctor involved with the screening. 
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2.1 Criteria for intervention: subjects fulfilling any of the following two criteria 
were considered for treatment with inhaled corticosteroids. 
A) A persistently low function (FEV, < 2 SD of the reference value on at 
least two of the initial four measurements, including the screening) or 
increased bronchial-hyperresponsiveness (BHR; PC20 histamine < 2 
mg/ml) combined with an increased reversibility (J>15% of reference 
value). 
B) Subjects with a decline greater than 80 ml at the end of the first year 
(after five assessments) combined with an increased BHR (PCM hist. <. 8 
mg/ml) or increased reversibility (>.10% of reference value). 
Statistical analysis. 
The number of subjects with a persistently low FEV, (reference value -2SD) or a 
rapid decline in FEV, (rate of decline > 80 ml/year) were identified for the at-
risk and control groups. The annual rate of decline in FEV, during the first year 
was calculated for both groups by means of linear regression analysis. The 
positive and negative predictive value of the screening test for detecting 
subjects with a persistently low lung function or a rapid decline in lung function 
was then calculated. The patient characteristics between groups were 
statistically compared by means of the unpaired t-test. 
4.4 Results 
Of the 1155 subjects screened, 604 (52%) were designated as "probably at-
risk". The predominant factor involved in this designation was the presence of 
respiratory symptoms. In total 388 subjects (64%) were designated exclusively 
on the basis of symptoms (Table-4.1A). Only 28 subjects (4.6%) were labelled 
as probably at risk exclusively on the basis of a reduced lung function and 2 
subjects solely on the basis of an increased BHR. The remaining 186 subjects 
had a combination of the four screening criteria. None of these criteria were 
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positive in the 551 subjects designated as not at risk. Of the 604 subjects 
labelled as probably at risk 384 consented to take part in the follow-up. No 
significant differences were found in demographic or clinical features between 
the 384 participants and 220 non participants (Table-4.2). 
Tabie-4.2: 
A Comparison of patient characteristics between healthy subjects and at-risk 
patients as measured during the screening. 
At-risk (n = 604) Healthy (n = 551) 
Participants Non-participants Participants Non-
participants 
Number 
Age (yr) 
%FEV, 
%Revers¡b¡li 
ty 
Packyears 
Symptom 
score 
384 
43.4 ± 
11.4 
93 ± 16 
4.3 ± 5.1 
8.9 ± 11.1 
1.2 ± 1.1 
220 
45 ± 13 
92 ± 15 
3.7 ± 5.1 
9.4 ± 1 1 . 4 
1.1 ± 1.1 
* 
* 
• 
* 
77 
42.4 ± 
10.7 
103 ± 12 
2.4 ± 2.7 
4.4 ± 6 " 
0.13 ± 0.4 
474 
43.5 ± 1 1 . 9 
101 ± 12.4 
2.4 ± 2.5 
7.4 ± 10 
0.1 ± 0.3 
%FEV, is the FEV, as a percentage of the reference value. (*) ρ <0.05 
comparison between groups (ie. at-risk participants versus healthy participants). 
(") ρ<0.05 comparison within group (ie. participants versus non-participants). 
From the subjects designated as not at risk, 77 were selected randomly for the 
follow up as a control group. The number of packyears was significantly lower 
in the control group (4.4) in comparison to the remaining 474 not-at-risk 
subjects (7.4). This difference was due to male smoking behaviour. The 
percentage of males in the control group was 45% with an average of 4.8 
packyears in comparison to 51 % of the 474 non-participants with an average of 
9.9 packyears. There was no difference in the number of smokers of the two 
groups (29% vs 31%). 
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A comparison of patient characteristics between the 384 at-risk subjects 
participating in the follow up and the 77 control subjects showed a significantly 
lower %FEV,, higher %reversibility, higher number of pack years and a higher 
symptom score for the former group even after stratification for gender, age and 
smoking (Table-4.2). 
We considered the presence of a persistently low FEV, (less than 2 SD of the 
reference value) as the objective indicator of mild OAD and calculated the 
positive and negative predictive value of the screening test for detecting this. A 
persistently low FEV, was found in 48 of the 384 at-risk subjects by means of 
the follow up. An increased BHR (PC20 <_ 8 mg/ml) was found in the majority of 
these subjects with a persistently low FEV,. Only 15 (31%) of these subjects 
had consulted the GP prior to the screening for airways related complaints. A 
persistently low FEV, was found in 6.9% of the sample screened by means of 
survival analysis after correction for the number of drop outs. None of the 77 
control subjects had a persistently low FEV,. The positive and negative 
predictive value was therefore respectively 12.5% and 100%. 
As mentioned in the design all subjects fulfilling the first criterion for 
intervention were withdrawn within the initial four assessments of the follow up 
in order to enable treatment. In total 54 subjects were withdrawn. A persistently 
low FEV, was found in 48 subjects and a PC20 less than 2 mg/ml combined with 
a %reversibility greater than 15% was found in six subjects. 
The remaining subjects who completed the first year of follow up (330 at risk 
and 77 controls) were divided into two sub-groups according to the magnitude 
of the rate of decline in FEV,. An annual rate of decline in FEV, exceeding 80 ml 
was found in 152 at risk subjects (46%) and 27 controls (35%). Of the 152 
subjects with a rapid decline in lung function, 79 also had an increased BHR or 
increased reversibility. The positive and negative predictive value of the 
screening test for distinguishing between subjects with a rapid decline and those 
with a normal decline was respectively 46% and 61 %. 
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4.5 Discussion 
This study demonstrates the possibility of detecting subjects with a persistently 
low lung function by screening the general population for respiratory symptoms 
and FEV,. A persistently low FEV, was found in 6.9% of the sample screened. 
The negative predictive value which is the hall mark of an effective screening 
test was 100%. However, the positive predictive value of this test was low. We 
also showed that it is not possible to distinguish between subjects with a rapid 
decline in FEV, and those with a normal decline by means of this screening test. 
Approximately half of the general population was labelled as probably being at-
risk for OAD as a result of our criteria during the screening. This seemingly 
alarming fact has to be interpreted with caution. Our aim was to detect subjects 
who are probably at-risk, at an early stage of the disease. Stricter criteria (such 
as serious respiratory symptoms combined with serious lung function 
abnormalities instead of either mild symptoms or mild lung function impairment) 
would have selected subjects with a serious form of the disease and not 
subjects who are probably at-risk. The seemingly high prevalence of subjects at-
risk was caused predominantly by the presence of respiratory symptoms. Only a 
minority of subjects were designated to this group on the basis of lung function 
abnormalities such as an FEV, less than 1.64 SD of the reference value or a 
reversibility greater than 15%. However, by means of post-screening lung 
function assessments we were able to detect 133 subjects with distinct airway 
abnormalities (48 with a persistently low lung function, 6 with a high 
BHR/reversibility, and 79 with a rapid decline in lung function combined with a 
moderately high BHR and reversibility). The screening should therefore be 
considered as an instrument in distinguishing between subjects with signs or 
symptoms of OAD, however mild they may be, from subjects with neither signs 
nor symptoms. 
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The current study also confirms the need for an active policy in detecting 
persons with OAD in the general population. All subjects with a persistently low 
lung function had at some stage experienced respiratory symptoms such as 
cough, sputum production or continuous or recurrent episodes of shortness of 
breath or wheeze. However, approximately two thirds of the subjects had never 
consulted a GP with regard to airway related symptoms prior to the screening. A 
cross-sectional comparison of a population survey conducted in 1977 with the 
current screening in 1992 reported similar findings, although other criteria were 
used for the diagnosis of OAD, in order to facilitate a proper comparison.21 
The main effect parameter in this study was the FEVV On basis of the FEV, 
subjects with a persistently low lung function could be classified as having a 
mild COPD ( > 7 0 % of the reference value).12 The majority of these subjects also 
had an increased BHR. These subjects may be considered as having an 
indication for treatment in order to prevent the development of symptoms and 
the occurrence of exacerbations, to preserve an optimal lung function and 
consequently to enhance general quality of life. None of the controls were found 
to have a persistently low FEV,. No information is available on BHR or 
reversibility in these subjects as it was not assessed in order to facilitate 
participation. 
The screening was unable to distinguish between subjects with a rapid decline 
and healthy subjects. A rapid decline was seen in 46% of the at-risk subjects at 
the end of the first year compared to 39% in the control group. It should 
therefore be emphasized that the presence of respiratory symptoms combined 
with a rapid decline in lung function assessed during a period of one year is not 
sufficient to categorize an individual as being in need of treatment. Other 
parameters such as BHR and reversibility should also be taken into 
consideration. 
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Subjects were withdrawn from the study at various stages as it was considered 
unethical to withhold them from proper treatment. The 48 subjects with a 
persistently low FEV, during the first six months and 79 subjects with a rapid 
decline during the first year who also had an increased BHR or increased 
reversibility were withdrawn from further analysis. Therefore eventual 
differences in the course of the lung function between the at-risk an control 
groups cannot be compared for the total duration of two years. 
It can be concluded that the active evaluation of respiratory symptoms and lung 
function is an effective method of detecting subjects with a mild, persistently 
impaired lung function at an early stage. It is not an effective method for 
distinguishing subjects with a rapid decline in lung function from those with a 
normal decline. The feasibility of implementing such a screening program in 
general practice needs further study. 
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5 Clinical relevance of reported symptoms of allergy and 
bronchial hyperresponsiveness 
5.1 Abstract 
Aim: We studied the clinical relevance of questions on bronchial 
hyperresponsiveness (BHR) and allergy in detecting patients with previously 
undiagnosed obstructive airway disease (OAD), with an indication for treatment, 
by screening the general population. 
Patients: A sample of the adult general population (n = 1155) was screened for 
respiratory symptoms, forced expiratory volume in one second (FEV,) and 
percentage reversibility of the airway obstruction. Subjects with either 
symptoms or lung function abnormalities entered a follow up study (n = 384). 
Symptoms and lung function was monitored once every three months. During 
this follow up, those with a FEV, < the predicted value minus two standard 
deviations on at least two occasions three months apart or patients with a high 
BHR (PC20 < 2mg/ml) combined with a high percentage reversibility (>15% of 
the predicted value) were defined as having a mild OAD with an indication for 
anti-inflammatory treatment. In total 54 subjects with no prior diagnosis of OAD 
fulfilled these criteria. 
Method: We assessed the individual responses to questions on BHR and allergy, 
during the screening, for the 54 subjects with an indication for treatment and 
the remaining 330. The validity of questions regarding BHR was studied by 
comparing the response to each of these questions with the results of the 
histamine provocation test. The validity of the allergy questions was studied by 
comparing the respective responses to the results of the skin prick test. The 
reproducibility of the questions was studied by means of a test-retest design. 
Results: The sensitivity and specificity of at least one positive response to either 
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the BHR or allergy questions in detecting patients in need of treatment during 
the screening was respectively 65% and 98% The positive and negative 
predictive value was respectively 9% and 98% The sensitivity of each BHR 
question considered separately ranged from 20-33%; the specificity 70-84% 
(positive predictive value ranged from 43-51%, negative predictive value from 
59-61%). The sensitivity of the allergy questions studied separately ranged from 
22-39%; the specificity ranged from 88-96% (positive predictive value ranged 
from 45-68% and the negative predictive value from 74-88%). Questions 
pertaining to BHR; cold air, mist, smog and those pertaining to allergy; pollen of 
grass, trees, flowers showed a good reproducibility (kappa > 0.7). 
Conclusion: A negative response to questions on either BHR or allergy indicated 
in the majority of cases the absence of OAD that needed treatment. A positive 
response to any of these questions appeared to have only a limited clinical 
relevance, and would require additional testing. 
5.2 Introduction 
Obstructive airway diseases such as asthma and COPD should not be a cause of 
serious morbidity or invalidity in present times when proper treatment is 
abundant.12 Dompeling et al have demonstrated the possibility of reducing the 
annual rate of decline in FEV, in patients with a progressive decline, by treating 
them with inhaled corticosteroids3. It has also been shown that the irreversible 
loss in FEV, can be limited by commencing treatment at an early stage of the 
disease4. It is therefore important to be able to detect patients at an early 
stage. 
There is evidence that some patients do not perceive the severity of respiratory 
symptoms,5 and that physicians experience problems in accurately diagnosing 
the severity of the disease at an early stage." This probably contributes to 
delays in treatment7. Delay in presenting or diagnosing OAD has been seconded 
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by the fact that morbidity figures on asthma in general practice is much less 
than the prevalence figures in population studies.6·89 '10,11 The various 
guidelines of the ATS,12 BTS,13 ERS14 and the Dutch College of General 
Practitioners (NHG)15 have been published to improve diagnosis and treatment 
of asthma. One of the objectives of these guidelines is to prevent 
underdiagnosis and delays in treatment. According to the guidelines the medical 
history should pay more attention to important features of asthma such as 
bronchial hyperresponsiveness (BHR) and allergy by inquiring after non-specific 
and specific triggers that cause respiratory symptoms. 
Modern day medical practice requires that more attention should be paid to the 
cost-effectiveness of diagnostic and therapeutical methods. The ideal situation 
would enable the general practitioner (GP) to obtain valid information on BHR 
and allergy by means of simple questions, while reserving the more expensive 
and complicated tests such as the histamine provocation test and the skin-
allergy test for selected cases. Respiratory symptoms have been reported to 
show a very poor correlation with the lung function on an individual basis.19 
However, until recently respiratory symptoms questionnaires were based on the 
Medical Research Council's (MRC) respiratory symptoms questionnaire17 and 
therefore assessed mainly symptoms of chronic bronchitis such as chronic 
cough and phlegm production. In recent years more emphasis has been given to 
asthma questionnaires.16 Dales et al have indicated that questionnaire 
information is not adequate for discriminating between subjects with and 
without increased reactivity in population screening.19 Burney et al on the 
other hand have shown that tightness in the chest following contact with animal 
dust or feathers is associated with an increased bronchial reactivity to 
histamine.20 
It is therefore important to know whether the poor correlation between 
symptoms and lung function seen in individuals can be improved by adding 
questions on BHR and allergy in order to reduce underdiagnosis of asthma. The 
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aim of this study was to investigate the clinical relevance (diagnostic value) of 
questions on BHR and allergy during screening for detecting subjects wi th OAD 
with an indication for treatment. Patients with an indication for treatment were 
defined as having chronic or recurrent respiratory symptoms in combination with 
a decreased FEV, or an increased BHR combined with an increased reversibility. 
These patients were detected in the general population; i.e. previously 
undiagnosed patients who would probably benefit if treatment is commenced at 
an early stage. 
5.3 Method 
Design. 
We screened a sample of the general adult population for respiratory symptoms 
and lung function in order to detect any subjects with a previously undiagnosed 
OAD, i.e. with early signs and symptoms. The results of this screening were 
used to investigate whether the relationship between the number of positive 
symptoms and %FEV, could be improved by adding questions on BHR and 
allergy. Patients found with early signs and symptoms of OAD during the 
screening were observed further in order to detect those with an indication for 
treatment. The predictive value of BHR and allergy questions for detecting such 
patients during the screening was then assessed. The validity of each BHR 
question was tested by comparing the response to the question with the 
measured PCJQ. The allergy questions were compared with the results of the 
skin tests. The Test-retest reliability of the questions on BHR and allergy was 
also assessed. 
Patient selection 
This was done by means of a two step design. 
Step 1 (screening): 1155 subjects were screened for respiratory symptoms, 
FEV, and percentage reversibility. Symptoms were assessed by means of the 
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translated and shortened version of the conventional MRC respiratory symptoms 
questionnaire21 (which mainly focused on symptoms of COPD and to a lesser 
extent on asthma) which was modified by adding questions on BHR and allergy 
(Table-5.1). The number of symptoms present during the past year was scored 
on a scale of 0-7 depending on the presence of five conventional items and two 
new items regarding BHR and allergy. The conventional questionnaire items 
were as follows, a) Cough during most days of three months; b) Phlegm 
production during most days of three months; c) Shortness of breath while 
hurrying on flat ground; d) Wheezing during the last 12 months; e) Asthma 
attack during the last 12 months. The two new questionnaire items were as 
follows (see Table-5.1). f) Respiratory symptoms (cough, wheeze, shortness of 
breath) caused by cold air, mist, smog etc; g) Respiratory symptoms (cough, 
wheeze, shortness of breath) caused by: animal danders, house dust, pollen. Of 
the 1155 subjects screened those with a symptom score greater than 1 (range 
0-7), or a FEV, less than the reference value minus 1.64SD, or an airway 
reversibility after the administration of salbutamol greater than 15% compared 
with the reference value were considered as having signs and symptoms of 
asthma. 
Table 5.1 
The following questions on BHR and allergy were added to the existing 
questionnaire 
la . BHR 
1 Do you start to cough or become wheezy or become breathless or do 
you feel a tightness around the chest in response to the following: 
1.1 household vapours and gases such as detergents, deodorants, 
hairspray, cooking vapours and paint? 
1.2 exercise? 
1.3 exhaust fumes 
1.4 cold air, mist, smog? 
1.5 cigarette smoke? 
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lb. Allergy 
2 Do you start to cough or become wheezy or become breathless or do 
you feel a tightness around the chest In response to the following: 
2.1 when you come in contact with pets, or with feathers? 
2.2 when you come in contact with house dust 
2.3 when you are in the vicinity of trees, grass, flowers or pollen? 
3 Do you have difficulty in breathing during certain seasons of the year? 
Step 2 (follow up): 384 patients with early signs and symptoms of asthma, 
detected during step-1, participated in the follow up. The FEV, and reversibility 
of these patients with one or more signs and symptoms of asthma was tested 
on three more occasions each three months apart. We analyzed this group 
further to detect patients with a previously undiagnosed OAD who were in fact 
in need of anti-inflammatory treatment. Patients with a reduced FEV, ( > 
%FEV,-2SD) on at least two of the four measurements, or PC20 < 2 combined 
with a reversibility > 15% of the predicted value were considered as being in 
need of treatment (n = 54). None of these 54 subjects were being treated for 
OAD prior to the screening. 
Forced Expiratory Volume in 1 second (FEV,) and the degree of reversibility. 
The FEV, was measured by means of an integrating flowmeter (Microspiro HI 
298, Chest Corporation, Tokyo, Japan)." Participants were instructed to 
refrain from bronchodilator therapy for at least 8 hours prior to the FEV, 
measurement. The participants were asked to perform three consecutive forced 
expiratory manoeuvres from maximum inspiration. The FEV, of the attempt with 
the highest sum of FEV, and FVC was retained for statistical analysis. The 
difference between the highest and the lowest FEV, values had to be less than 
0.1 Litre. The measurements took place during exacerbation-free periods. The 
patient was then administered 800 μ$ salbutamol by inhalation, immediately 
after the base-line measurements. The FEV, was measured again after 15 
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minutes. The degree of reversibility was defined as the change in FEV, as a 
percentage of the predicted value.23 
The provocational concentration of histamine (PC20). 
This was assessed according to the method described by Cockcroft et al.2 4 
After base-line spirometry an aerosol of buffered saline and aerosols of 
histamine acid phosphate in doubling concentrations from 0.03 to 32 mg/ml 
were administered at five-minute intervals. Spirometry was repeated 30 and 90 
seconds after each inhalation. The provocational concentration of histamine 
causing a 20% fall in FEV, from the base-line value (PCM) was considered as 
the magnitude of BHR. Patients with a PC20 less or equal to 8 mg/ml were 
considered as having a positive BHR. 
The skin allergy test. 
The patient was considered allergic if at least one of following skin tests for 
common inhaled allergens showed a skin reaction _> 0,7 of the reaction to 
histamine. 1) wind borne pollens such as Timothy grass, ragweed, tree, flowers; 
2) animal danders of cat, dog, sheep, chicken, rabbits and hamsters; 3) house 
dust mite and 4) fungal spores. 
Test-retest reliability. 
During the screening a random sample of 98 participants were administered the 
respiratory symptoms questionnaire twice within a span of 8 weeks. 
Statistical analysis 
The patient characteristics of those with an indication for treatment (n = 54) was 
compared to those with no indication for treatment (n = 330). Allergy was tested 
by means of the chi-square test; all other variables by means of the unpaired t-
test. The clinical relevance of questions on BHR and allergy for detecting 
patients with an indication for treatment by means of a screening-test was 
studied by comparing the questionnaire response of the 54 patients with that of 
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the remaining 1101 screened. The sensitivity, specificity, positive and negative 
predictive values were calculated. Data of the 384 patients with signs and 
symptoms of asthma was used to study the validity of the questions by 
comparing the subjective questionnaire response to the objective test result. The 
sensitivity, specificity, positive and negative predictive values were calculated. 
For the test-retest reliability we calculated the correlation (Kappa) between the 
response to a given question during the first administration and the response to 
the same question during the second administration. Questions with a 
correlation coefficient greater than 0.6 were considered reliable. 
5.4 Results 
We detected 54 subjects with a mild OAD and an indication for treatment. 
Patient characteristics such as age, lung function, symptom score, number of 
packyears, BHR and allergy of these patients were compared to that of the 
remaining 330 patients with early signs and symptoms (Table-5.2). There was 
no difference in age between the two groups. The vital capacity (VC), FEV,, 
%FEV, and logPCjo were significantly lower in patients with an indication for 
treatment. The number of packyears and the symptom score were significantly 
higher in this group. 
The relationship between the FEV, and the symptom score in the 1155 subjects 
screened. 
Figure-5.1 shows the relationship of the mean %FEV, ± SD and symptoms 
measured by means of the five conventional questions regarding a) cough, b) 
phlegm, c) shortness of breath on exertion, d) wheeze and e) asthma attacks. A 
very low but significant correlation was seen between the %FEV1 and the 
number of positive symptoms (r = -0.2; p<0.05). Figure-5.2 shows the effect 
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when the questions on f) BHR and g) allergy, were added to the above five 
questions. There was no improvement in the correlation (r = -0.18; ρ <0.05). 
Table 5.2 
The patient characteristics of the group with an indication for treatment was 
compared with the group with only early signs and symptoms. 
Patient 
characteristics 
Age (years) 
VC (ml) 
FEV, (ml/sec) 
%FEV, (%) 
Reversibility (%) 
Packyears 
Symptom score 
logPC20 
Allergy (%) 
Patients with an 
indication for 
treatment (n = 54) 
4 4 ( 1 2 ) 
3336 (843) 
2315 (520) 
70.6 (10.2) 
6.2 (8.7) 
13.3 (13.9) 
1.9 (1.5) 
0.8 (3.44) 
44.4 
No indication for 
treatment 
(n = 330) 
4 3 ( 1 1 ) 
4115 (1043) 
3238 (753) 
96.5 (13.2) 
4.0 (4.1) 
8.2 (10.4) 
1.3 (1.2) 
3.3 (2.4) 
35.8 
Ρ value 
0.3 
0.0000 
0.0001 
0.0001 
0.06 
0.01 
0.007 
0.0001 
0.2 
Table 5.3 
The sensitivity and specificity of at least one positive response to BHR questions 
or one positive response to allergy questions or one positive response to either 
BHR or allergy questions for detecting patients with an indication for treatment 
during the screening. 
At least 1 positive 
response t o : 
BHR questions 
Allergy questions 
either BHR or 
allergy questions 
Diagnosis "in need of treatment" 
Sensitivity (%) Specificity (%) 
61.1 71.9 
31.5 85.9 
64.8 66.6 
Predictive value (%) 
Positive Negative 
9.6 97.4 
9.9 96.2 
8.7 97.5 
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The clinical relevance of BHR and allergy questions In detecting patients with an 
indication for treatment by means of a screening-test. 
The sensitivity, specificity, positive and negative predictive values are shown in 
Table-5.3. Thirty-three (61.1%) of the 54 patients with an indication for 
treatment had a positive response to at least one of BHR questions (question 
no:1.1-1.5) in comparison to 309 (28.1%) of the remaining 1101 patients 
screened. For the questions regarding allergy this was 17 (31.5%) and 155 
(14.1%) for the two respective groups. For either BHR or allergy questions this 
was 35 (64.8%) for the 54 patients and 368 (33.4%) for the remaining 1101 
patients. The specificity of at least one positive response to the BHR questions 
was 71.9%, for allergy 85.9% and either BHR or allergy 66.6%. The positive 
predictive value of the questions for detecting patients with an indication for 
treatment was for BHR 9.6%, allergy 9.9% and either BHR or allergy 8.7%. The 
negative predictive value was for BHR 97.4%, allergy 96.2% and either BHR or 
allergy 97.5%. 
Validity of each question separately 
Table-5.4 shows the response to each BHR question (regarding a given non-
specific irritant; Table-5.1: questions 1.1-1.5) in relation to the objective result 
of the histamine provocation test. The sensitivity of each of the five questions 
ranged from 20-33%. The specificity ranged from 70-84%. The positive 
predictive value ranged from 4 3 - 5 1 % and the negative predictive value ranged 
from 59 -61%. Table-5.4 also shows the results of similar calculations for the 
allergy questions (Table-5.1: questions 2.1-3). The sensitivity of these four 
questions ranged from 22-39%. The specificity ranged from 88-96%. The 
positive predictive value ranged from 45-68% and the negative predictive value 
from 74-88%. 
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r - -0.2 
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η =1155 
— 
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Number of positive symptoms 
Figure 5.1: Lung function vs symptom score as measured by the five 
conventional questionnaire items. 
Breathing space; deep breaths in and out, in and out. 
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%FEV1 
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r --0.18 
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Number of positive symptoms 
Figure 5.2: Lung function vs symptom score as measured by seven 
questionnaire items. 
Test-retest reliability 
Respiratory symptoms caused by cold air, mist, smog and symptoms caused by 
pollen of grass, trees, flowers had a Spearman correlation coefficient and Kappa 
greater than 0.7. Symptoms caused by household vapours, gases and 
symptoms caused by house dust and symptoms during certain seasons of the 
year had a correlation coefficient and kappa value between 0.5 and 0.7. the 
correlation coefficient and kappa of the remaining questions was less than 0.5 
(see Table-5.4). 
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5.5 Discussion 
The aim of this study was to assess the diagnostic value of questions on BHR 
and allergy in detecting patients with a previously undiagnosed OAD with an 
indication for treatment by means of screening the general population. This 
study shows that subjects with a negative response to all questions during the 
screening are in most cases (97.5%) not in need of treatment. This may have 
important clinical consequences. A positive response to any of the questions on 
specific and non-specific triggers that cause respiratory symptoms have a low 
predictive value in detecting such patients. The reproducibility of these 
questions was generally low with the exception of questions regarding cold air, 
mist, smog and pollen of grass, trees, flowers. 
This study shows a weak but significant relationship between reported 
symptoms and FEV,, similar to the findings of Boezen et al.25 The clinical value 
of symptoms in predicting the lung function in a given individual is low. The 
addition of new questions on BHR and allergy did not improve this correlation. It 
is therefore possible for individuals with more than one symptom to have a 
normal FEV, and individuals with no symptoms to have a reduced FEV,. The 
general practitioner is likely to be less alert about the presence of airway 
obstruction in the latter group than in the former which can give rise to 
underdiagnosis and delays in treatment. This might be an explanation to the fact 
that there are undetected asthmatics in the general population who are in need 
of treatment, which was the case in this random population sample. This once 
again shows the need for better methods of detection. 
BHR is considered one of the important diagnostic criteria in patients with 
asthma.28 The histamine provocation test for determining the degree of BHR 
provides vital information regarding the patient's medical status. However, these 
tests are complicated and time consuming and are usually done in specialized 
laboratories. In practice this is a barrier for the GP to request such a test in 
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seemingly innocent situations (i.e. patients with only mild symptoms). It was 
therefore important to investigate whether a respiratory symptoms questionnaire 
can replace such tests. Our study shows that each question on non-specific 
irritants, taken separately cannot replace the histamine provocation test, i.e the 
sensitivity is low. The same is true for questions on allergy. 
Epidemiological studies have shown that a positive answer to questions on 
wheeze, cough, phlegm and dyspnoea on exertion correlate well with a low 
PCJ0.27 Such questions have therefore been suggested to have a high 
predictive value of BHR. Rijcken et al. have shown that patients with wheeze 
and dyspnoea have in general a high BHR, patients with cough and phlegm have 
an intermediate BHR and asymptomatic individuals a low BHR.27 Our 
questionnaire also consisted of the above questions. These questions are 
considered as conventional questions commonly used in epidemiological studies. 
We investigated the additional value of new questions which apparently seem to 
be directly associated with BHR. Our study however, shows a low predictive 
value of the new questions for BHR. 
The low reproducibility of the questions on BHR and allergy cannot be explained 
by the variation of respiratory symptoms in time (eg. seasonal variation) as the 
retest was done within a relatively short period of 8 weeks. This would possibly 
be true for a longer time interval between test and retest. A possible explanation 
is that the low reproducibility might be caused by different interpretations of the 
questions by the patient. However, this low reproducibility was not inherent to 
the new questions only, but was also observed in the conventional questions 
from validated questionnaires. The reproducibility of almost all conventional 
questions were less than 0.6. 
Venables et al. tested the validity and reproducibility of a questionnaire for use 
in epidemiological research in asthma.18 Two of the nine questions, i.e. "do you 
wheeze in a smoky room", and "do you wheeze in a dusty place" were 
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approximately similar to our new questions. The above mentioned study 
reported that the presence of the combination of two or three symptoms 
appeared to be good indices for reported asthma and BHR, with a sensitivity 
(65-91%) and specificity of (85-96%). Our study showed that the presence of 
at least one of the BHR or allergy symptoms had a sensitivity of 65% and a 
specificity of 66% in detecting patients with an indication for treatment. These 
indices for each question separately was however much lower. 
In most cases asthma or COPD can be diagnosed by means of the medical 
history (typical episodic pattern of symptoms). This episodic pattern however 
might not be apparent during a specific consultation.28 It is therefore important 
to check the records for previous respiratory consultations. If this is not 
available it is important to obtain an accurate past medical history. It is also 
important to consider OAD as a possible diagnosis at every consultation 
regarding respiratory symptoms. 
In conclusion, questions on non-specific and specific triggers provide very little 
additional information regarding the bronchial responsiveness and allergy status 
of the patient. Therefore these questions cannot replace objective 
measurements such as the histamine provocation test and skin tests. 
Nevertheless these questions might make a contribution to diagnosis in the 
primary care setting as when all questions on BHR and allergy are considered 
together it has a very high negative predictive value. This means that a negative 
response to all questions shows that the patient is not in need of treatment. 
Further testing (PC20 and skin-tests) is not indicated in these patients. If at least 
one of the new questions is positive then further testing might be indicated. 
This way a more thorough history taking could select patients for further 
testing. 
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6 The detection of a rapid decline in FEV-, at an early 
stage; the duration and number of measurements 
needed for an accurate estimation of the decline in FEV, 
6.1 Abstract 
Background: It is essential to detect and treat patients with a rapid rate of decline 
in FEV, at an early stage. The accuracy of the measured rate of decline shows a 
considerable variability. The aim of this study was to investigate the effect of the 
duration of the observation period and frequency of measurements on this 
accuracy. 
Method: The annual rate of decline was calculated by means of linear regression 
analysis. The influence of the duration of the observation period and the 
frequency of measurements, on the standard deviation of this measured decline 
was calculated. An annual rate of decline above 0.04 Litres was considered as a 
rapid decline. We then calculated the probability that an individual with a given 
measured rate of decline, would in reality have a decline greater than 0.04 L/year. 
Results: The accuracy of the measured rate of decline is more influenced by the 
duration of the observation period than the frequency of measurements. Only 
individuals with a measured decline of ± 0.16 L/year can be diagnosed safely as 
having a rapid decline with an observation period of one year. A period of at least 
two years is needed to diagnose individuals with a decline of ± 0.1 L/year 
accurately. 
Conclusions: We consider measuring the FEV, during a period of two years with 
a frequency of once every 3 or 6 months sufficient for diagnosing individuals with 
a moderate to severe increased rate of decline. These individuals should be 
detected at an early stage of their disease as they have the most to benefit by 
early treatment. 
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6.2 Introduction 
It is important to detect patients with a rapid decline in FEV, at an early stage. 
Adequate treatment of such patients with inhaled corticosteroids, has been 
shown to reduce this rate of decline, i.e. limit the irreversible loss in lung 
function, which can be an advantage for the patient in the long run1,2. However, 
little is known on how to detect such patients with a rapid decline in FEV, at an 
early stage. 
The annual rate of decline in FEV, in adults is seen as the most important index 
for assessing severity, for estimating progression and for predicting mortality in 
asthma and COPD3. The FEV, shows a physiological, linear decline after the age 
of 18 - 25 years4,5. The rate of decline in FEV, is greater in patients with asthma 
and COPD in comparison to healthy subjects36. Monitoring the FEV, during a 
period of time is therefore of vital importance in determining this rate of decline. 
If the FEV, is determined at a particular moment (T0) and then measured again 
after a period of time (Tt), the change in FEV, occurring within this period of time 
could be calculated as the difference between T0 and T, divided by the period of 
time7. However, this will seldom be an accurate estimate of the slope, as the 
FEV, measured at T0 or Tt can vary greatly8-9. This cross-sectional variability 
depends on different factors such as errors of measurement caused by the 
apparatus, by the observer and by the patient10. The error caused by most 
modern apparatus is very low11. The errors caused by the observer and patient 
could be reduced by following the standardized procedures for lung function 
testing12. However, the intra-individual (biologic) variation would still effect the 
accuracy of the estimated slope. 
A minimum duration of the observation period is needed in order to detect a 
biological change in the FEV, in time. Schrader et.al13 have described a method 
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to estimate this minimum period of time. Their results show that a period of at 
least one year is needed to elucidate the natural changes in FEV, in adolescents. 
Different factors that may influence the accuracy of the estimated decline in FEV, 
are given below. 
1 ) intra-individual (biologic) variation8, 
2) Duration of the observation period14-15 
3) Frequency of measurements14, 
It is important to understand how these factors effect the accuracy of the 
estimated decline in FEV, in an individual. The reported annual rate of decline in 
FEV, in asthmatics, patients with COPD and healthy subjects in the literature 
varies greatly. The frequency of measurements and the duration of the 
observation period in these studies also differ widely, ranging in frequencies from 
once every 6 months to once in 10 years with observation periods varying from 1 
to 18 years.3'4e·19"31 Reference values for normal and pathological decline in lung 
function have been shown to be far from unanimous16. This is true even today. It 
is therefore of utmost importance to standardise the procedures used to 
determine the rate of decline in FEV, with time. The decline in FEV, measured 
under such standardised conditions would provide better information about the 
diagnosis and management of patients with chronic airflow limitation. 
The aim of this study was to investigate the effect of the frequency of 
measurements and the duration of the observation period on the accuracy of the 
measured annual rate of decline of an individual. This with special regard to the 
possibility of detecting patients with a severely increased rate of decline in FEV, 
at an early stage. 
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6.3 Methods 
The IBM 370 main frame of the University of Nijmegen was used to calculate the 
annual rate of decline in FEV, and its standard deviation (error) for a theoretical 
individual. These calculations were based on the equations explained below32. 
Tables 1 and 2 were constructed by using these equations. 
The decline in FEV, in adults was assumed to be linear. The relationship between 
the FEV, and time is shown in the following equation. The time interval between 
the measurements was kept constant (equidistant). 
Equation 1: FBV.U) « a • bit) 
FEV,(t) = measured value at a given time (t); a = Constant; b = Regression 
coefficient; t = Moment of measurement) 
The regression coefficient (b) corresponds to the decline in FEV,, measured within 
the given observation period. It is however, important to know the accuracy of 
this estimate. The accuracy of the measured decline, defined as the standard 
deviation of the measured decline, was calculated by means of the following 
equation. 
Equation 2: _
 o ( y ) 
o(b) 
o(t) • /гпт 
a(b) = Standard deviation of the estimated rate of decline for an individual; a(y) = 
Intra-individual (biological) variation; σ(ΐ)= Standard deviation of t; f = Number of 
measurements 
In this study the intra-individual variation [σ(γ)1 was considered to be constant 
(0.1 Litre) in order to visualise the effect of the other factors on the accuracy of 
the decline. The other factors are the standard deviation of the points of 
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measurement [σ(\)\ and the number of measurements [f] which was interpreted as 
the duration of the observation period and the frequency of measurements 
respectively. By using different hypothetical values for <r(t) and f in equation 2, it 
was possible to calculate an error factor 1/[a(t) * V(f-1)], which when multiplied 
by the intra-individual variation [σ(γ)] provides the standard deviation or error of 
the measured rate of decline in FEV, [a(b)]. 
The standard deviation of the measured decline can be decreased, i.e. the 
accuracy of this estimate can be increased, by increasing the product of [σ(\)] and 
h/(f-1)] (see equation 2). This was done by increasing the interval between 
measurements [σ(\)\ and the number of measurements (f). The interval between 
measurements can be increased by increasing the duration of the observation 
period while the number of measurements is kept constant. 
For the purpose of detecting patients, we assumed an annual rate of decline of 
0.04 L. to be the threshold between a normal and a rapid decline (For treating 
patients an annual decline of 0.08L was considered as the threshold). A measured 
annual rate of decline higher than 0.04 L could therefore be regarded as a rapid 
decline in lung function. The real (biological) decline in FEV, in an individual was 
assumed to show a normal distribution. We calculated the probability of correctly 
diagnosing an individual with a real rapid decline by means of the measured rate 
of decline in FEV, and its standard deviation. This was done by means of the 
following equation. 
Equation 3: . . . 
P [ Ь> 40 ] = Ρ [ ζ > ( - ^ £ ) ] 
Ο KD) 
Ρ = Probability; Ζ = Standardized deviate; b = Estimated rate of decline; 
a(b) = Standard deviation of the estimated rate of decline for an individual 
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6.4 Results 
Table-6.1 shows the magnitude of the error factor 1/[a(t) * "/(M)] for various 
durations of the observation period and various numbers of measurements made 
within the respective duration (equation 2). The columns show the duration of the 
observation-period which varies from 1 to 10 units (week, month, year). For this 
study we considered the time period in years. The rows show the number of 
measurements made during this observation-period and varies from 2 to 37. This 
error factor when multiplied by the intra-individual variation [σ(γ)] gives the 
standard deviation (error) of the measured rate of decline [a(b)]. For example, if 
the FEV, of an individual is measured five times during a period of one year (i.e. 
once every three months), the error factor for the measured rate of decline will be 
1.26. If the intra-individual variation of this individual is assumed to be 0.1 Litres, 
the standard deviation of the measured rate of decline will be 0.126 L. 
Table 6.1: 
The error factor calculated for various durations of observation periods and various numbers of 
measurements made during the respective period. 
No. of Poriod of observation (years) -* 
imMuraimnt· 
2 
3 
4 
6 
β 
7 
8 
9 
10 
13 
25 
3 7 
1 
1.41 
1.41 
1.34 
1.2β 
1.20 
1.13 
1.08 
1.03 
0.99 
0.89 
0.87 
0.55 
2 
0.71 
0.71 
0.67 
0.63 
0.60 
0.57 
0.54 
0.52 
0.50 
0.45 
0.33 
0.28 
Э 
0.47 
0.47 
0.45 
0.42 
0.40 
0.38 
0.36 
0.34 
0.30 
0.30 
0.22 
0.19 
4 
0.35 
0.35 
0.34 
0.32 
0.30 
0.28 
0.27 
0.26 
0.25 
0.23 
0.17 
0.14 
Б 
0.28 
0.28 
0.27 
0.25 
0.24 
0.23 
0.22 
0.21 
0.20 
0.18 
0.13 
0.11 
β 
0.24 
0.24 
0.22 
0.21 
0.20 
0.19 
0.18 
0.17 
0.17 
0.15 
0.11 
0.09 
7 
0.20 
0.20 
0.19 
0.18 
0.17 
0.16 
0.15 
0.15 
0.14 
0.13 
0.09 
0.08 
β 
0.18 
0.18 
0.17 
0.16 
0.15 
0.14 
0.14 
0.13 
0.12 
0.11 
0.08 
0.07 
9 
0.16 
0.16 
0.15 
0.14 
0.13 
0.13 
0.12 
0.11 
0.11 
0.10 
0.07 
0.06 
10 
0.14 
0.14 
0.13 
0.13 
0.12 
0.11 
0.11 
0.10 
0.10 
0.09 
0.06 
0.05 
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ТаЫе-6.1 also shows the effect of the duration of the observation period on the error factor when 
the number of measurements is kept constant. If the FEV, of an individual is measured five times 
during a period of one year, the standard deviation of the measured decline would be 0.126 L. If 
the FEV, is measured five times during a period of 2 years (i.e.once every six months), the 
standard deviation of the measured decline will be halved to 0.063 L. A further doubling of the 
duration to 4 years with the same five measurements (once every year) shows a standard 
deviation of 0.032 L. 
If the duration of the observation period is kept constant, for example one year, and the number 
of measurements made in that year is doubled from 5 to 10 the error factor of the measured rate 
of decline will only decrease from 1.26 to 0.99. 
Table 6.2 
The probability of having a real (natural) rate of decline greater than 0.04 Uyear (rapid decline), 
for a given measured rate of decline and corresponding standard deviation. 
Tha maaaurad The standard deviation of tha maaaurad decline oibl in Utraa 
decline 
0.06 L 
0.0« L 
0.07 L 
0.08 L 
0.09 L 
0.10 L 
0.11 L 
0.12 L 
0.13 L 
0.14 L 
0.15 L 
0.16 L 
0.02 
6 9 % 
8 4 % 
9 3 % 
9 8 % 
9 9 % 
9 9 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
0.04 
6 0 % 
6 9 % 
7 7 % 
8 4 % 
8 9 % 
9 3 % 
9 6 % 
9 8 % 
9 9 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
o.oe 
5 7 % 
6 3 % 
6 9 % 
7 4 % 
8 0 % 
8 4 % 
8 7 % 
9 1 % 
9 3 % 
9 5 % 
9 7 % 
9 8 % 
o.oe 
5 5 % 
6 0 % 
6 5 % 
6 9 % 
7 3 % 
7 7 % 
8 1 % 
8 4 % 
8 7 % 
8 9 % 
9 2 % 
9 3 % 
0.10 
5 4 % 
5 8 % 
6 2 % 
6 6 % 
6 9 % 
7 3 % 
7 6 % 
7 9 % 
8 2 % 
8 4 % 
8 6 % 
8 8 % 
0.12 
5 3 % 
5 7 % 
6 0 % 
6 3 % 
6 6 % 
6 9 % 
7 2 % 
7 5 % 
7 7 % 
8 0 % 
8 2 % 
8 4 % 
0.14 
5 3 % 
5 6 % 
5 8 % 
6 1 % 
6 4 % 
6 7 % 
6 9 % 
7 2 % 
7 4 % 
7 6 % 
7 8 % 
8 0 % 
Table-6.2 shows the probability of having a real rapid decline (natural rate of 
decline greater than 0.04 L/year), for a given measured rate of decline and 
corresponding standard deviation. In the above example, an individual measured 
five times during one year showed a standard deviation of the measured decline 
of 0.126 L. If we assume that the measured rate of decline (calculated by means 
of linear regression analysis of these five points) is 0.06 L/year, the probability of 
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this individual having a real rapid decline would be 56%. This means the 
probability of a correct diagnosis is ± 56%, while the probability of a false 
positive diagnosis (i.e. natural decline less than 0.04 L/year) will be ± 44%. 
Table-6.3 is a summary of Tables 6.1 and 6.2 which provide an easy reference of 
the effect of the duration, frequency and measured rate of decline on the 
probability of a correct diagnosis. An individual with a measured annual rate of 
decline of 0.06 L (mild increase in the rate of decline), during a period of one year 
with a frequency of once every three months (number of measurements is five), 
would have a probability of 56% for being diagnosed correctly. If the measured 
decline was 0.1 L (moderate increase), then the probability would be 68%, and if 
the measured rate of decline was 0.16 L (severe decline) then the probability 
would be 83%. If the same frequency is considered for a duration of 2 years the 
probability of correctly diagnosing a patient with a mild increase in the rate of 
decline would increase to 65% and for a moderate and severe decline to 87% 
and 99% respectively. 
Table 6.3: The effect of the duration and frequency on the probability of having a real rapid 
decline for various measured rates of decline and corresponding standard deviations. The standard 
deviation is a product of the error factor and the intra-individual variation. The latter was assumed 
to be 0.1 L. 
Duration In Number of meeeurements standard Tha probability of having a raal rapid daellna whan 
yeere (fraquancy) deviation (0bl tha measured rete of decline bj: 
3 (onca every 6 months) 
5 (once every 3 months) 
13 (once every month) 
5 (once every β months) 
9 (once every 3 months) 
25 (once every month) 
7 (once every β months) 
13 (once every 3 months) 
37 (ones every month) 
13 (once every 6 months) 
25 (once every 3 months) 
In Utree 
0.141 
0.126 
0.089 
0.063 
0.052 
0.033 
0.038 
0.030 
0.019 
0.015 
0.011 
0.06 Uveer 
(MILD) 
5 5 . 5 % 
5 6 . 3 % 
5 8 . 7 % 
6 2 . 5 % 
6 4 . 8 % 
7 2 . 9 % 
7 0 . 1 % 
7 4 . 8 % 
8 5 . 3 % 
9 0 . 6 % 
9 6 . 5 % 
O.IOL/vear 
(MODERATE) 
6 6 . 6 % 
6 8 . 4 % 
7 4 . 8 % 
8 2 . 8 % 
8 7 . 4 % 
9 6 . 5 % 
9 4 . 2 % 
9 7 . 7 % 
9 9 . 9 % 
1 0 0 % 
1 0 0 % 
O.ieWvear 
(SEVERE) 
8 0 . 2 % 
8 2 . 8 % 
9 1 . 1 % 
9 7 . 1 % 
9 8 . 9 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
1 0 0 % 
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If an individual with a mild increase in the rate of decline is monitored once every 
month during a period of one year the probability of a correct diagnosis would be 
59%, in comparison to a probability of 56% when monitored once every three 
months. For a period of two, three and six years this would be 73%, 85% and 
97% respectively. 
6.5 Discussion 
The results show that the duration of the observation period has a greater 
influence on the accuracy of the measured decline than the frequency of 
measurements. An observation period of two years is needed to diagnose 
individuals with a moderate to severe increase in the annual rate of decline, 
although a very severe rate of decline (eg. 2.0 L/yr) can be diagnosed correctly in 
most cases within a period of one year. A longer observation period than two 
years is needed to diagnose individuals with a mild increase in the annual rate of 
decline. 
A doubling of the duration of the observation period shows a reduction in the 
standard deviation of the measured decline, ie. an increase in accuracy, by 
approximately 50%. A doubling of the frequency also shows a reduction in the 
standard deviation but of a much lower magnitude. The accuracy of the measured 
rate of decline is therefore more susceptible to changes in the duration than to 
changes in the frequency of measurements. This finding can be considered as a 
statistical confirmation of earlier observations made by Burrows et.al.14 
In patient care it is of vital importance to know whether the patient in concern 
has an increased rate of decline in lung function, as the decision to commence 
treatment may depend on this. Priority should therefore be given to diagnosing 
individuals with a severely increased rate of decline (eg. 0.16 L/year) as soon as 
possible. The results show that 83% of such cases can de diagnosed correctly 
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with an observation period of one year. With an observation period of two years 
99% of these individuals could be diagnosed correctly, as well as 87% of 
individuals with a moderate decline (0.1 L/year). 
It is important to note that an individual with a mild increase in the annual rate of 
decline cannot be diagnosed correctly within a duration of one year even if the 
frequency of measurements is increased to once every month. Even an 
observation period of two years is not convincing in this case, and a longer 
duration will be necessary. Our results show that a duration of approximately six 
years is needed to correctly diagnose individuals with a mildly increased rate of 
decline. Dales et.al15 showed in their study that six years of follow up is needed 
to detect an annual decline of 0.045 L/yr. 
We conclude that the FEV, measured regularly during a period of 2 years, allows 
the proper detection of individuals with a real rapid decline in FEV, at an early 
stage, especially those with a high annual decline in FEV, who have the most to 
gain by early treatment. For detecting individuals with a mild decrease a longer 
period is necessary. For clinical practice this is an important message as a rapid 
decline is of more clinical value when patients are urgently in need of treatment 
which is probably the case when patients have a rapid decline in lung function. 
These conclusions based on statistical expectations provide basic information 
necessary for clinical decision making. They should be considered as possible 
guidelines for estimating the annual rate of decline in FEV, for a given individual 
(not for analyzing groups). Each investigator should consider technical aspects 
such as the accuracy of the decline which is considered acceptable and practical 
aspects such as work-load, finances and doctors-delay in choosing an appropriate 
duration and frequency to monitor the FEV,. 
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7 Evaluation of the suitability of weekly peak 
expiratory flow rate measurements in monitoring 
annual decline in lung function among patients with 
asthma and chronic bronchitis 
7.1 Abstract 
Background: Early detection and treatment of patients with asthma or chronic 
bronchitis who have a rapid annual decline in lung function is essential in order 
to improve their long term prognosis. This annual rate of decline can be 
assessed accurately by monitoring the forced expiratory volume in one second 
(FEV,) which is a routine procedure in hospital respiratory laboratories but not in 
general practice. General practitioners usually measure patients' peak expiratory 
flow rate (peak flow) to evaluate lung function. If annual decline in lung function 
can be assessed by monitoring peak flow, this method could be used in general 
practice for detecting patients at an early stage who have a rapid decline. 
Aim: A study aimed to investigate the long-term correlation between FEV, and 
peak flow among a group of patients in Nijmegen, the Netherlands. 
Method: FEV, and peak flow were monitored in 53 patients with moderate 
asthma and 78 patients with moderate chronic bronchitis over four years. FEV, 
was measured in a laboratory once every six months and peak flow was 
measured by patients once a week. The correlation between the two sets of 
measurements was studied for each patient. 
Results: Four-year data for 83 of the 131 patients analyzed; the other 48 
patients received inhaled steroids during the second half of the study period so 
their data were not considered for all the analyses. Of the 83 patients, 35 
(42%) showed a decrease in both FEV, and peak flow. Thirty six patients (43%) 
showed a decrease in the FEV, and an increase in peak flow. Four patients (5%) 
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showed an increase in FEV, and a decrease in peak flow and eight (10%) 
showed an increase in both rates. Approximately similar results were seen in a 
separate analysis of all 131 patients during the first two years of the study. 
Conclusion: No long-term correlation was found between FEV, and peak flow. 
Peak flow is not capable of detecting annual decline in lung function. Therefore 
it cannot be used to detect patients with asthma or chronic bronchitis who have 
a rapid annual decline in lung function. Spirometers, which measure peak flow 
and FEV,, could be used in general practice. These would allow the general 
practitioners to continue measuring peak flow in order to assess short-term 
changes in lung function while providing an important means for monitoring 
FEV1# to assess long-term changes in lung function. 
7.2 Introduction 
There is an increased appreciation of the importance of using objective 
parameters such as peak expiratory flow rate (peak flow) in the diagnosis and 
treatment of patients with asthma and chronic bronchitis (chronic obstructive 
pulmonary disease).1,2 The peak flow represents the maximum flow of air 
attained during a forced expiratory manoeuvre and corresponds to the peak on a 
flow-volume curve. This maximum flow during expiration is reduced in patients 
with airway obstruction, for example those with asthma or chronic bronchitis. 
The rate has been shown to be a simple and reproducible parameter in assessing 
airway obstruction.3 The peak flow meter is a cheap and simple device that is 
commonly used in general practice and by asthmatic patients in self-
management programmes. A patient's measured peak flow value can be 
compared with a predicted value (obtained from standard reference charts) or 
with the patient's personal best (measured during a symptom free period) to 
determine the presence or absence of airway obstruction. Other common uses 
of peak flow measurements are in the assessment of diurnal variability, day-to-
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day variability and reversibility of airway obstruction.4 The greater the variability 
the more prone are the airways to bronchial constriction. 
The forced expiratory volume in one second (FEV,) is another objective 
parameter which has been established as the best measure for assessing 
severity of airway obstruction.3 Owing to the complexity and high costs of the 
necessary apparatus it has until recently only been used in hospital respiratory 
laboratories. Since the introduction of portable, easy-to-use, low cost spirome-
ters, patients' FEV, is occasionally being measured in general practice. FEV, has 
been shown to be an important index for assessing severity of airway 
obstruction and for estimating its progression and is so far the only parameter 
that has been shown to predict asthma mortality.5 In adults, FEV, shows a 
physiological decline with age.6,7 This annual rate of decline is greater in asthma 
and chronic bronchitis sufferers compared with non-sufferers." It is possible to 
detect patients with a high annual rate of decline in lung function by means of 
serial FEV, measurements. Early detection followed by adequate treatment of 
such patients has been shown to reduce this rate of decline, thereby improving 
patients' long term prognosis.9 
FEV, and peak flow measurements show a close correlation in cross-sectional 
studies.10 Although many longitudinal studies have investigated the course of 
FEV, over time, little is known about the course of peak flow over time and its 
long-term correlation with FEV,. If peak flow is shown to have a close long-term 
correlation with FEV, it could also be used in general practice to detect patients 
with a fast, progressive form of asthma or chronic bronchitis. A study was 
carried out to investigate the long-term correlation between FEV, and peak flow. 
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7.3 Method 
Patient selection and participation 
The study was approved by the medical ethics committee of the University of 
Nijmegen, the Netherlands. Twenty nine general practitioners in the catchment 
area of the university selected patients for the four-year study. A total of 223 
patients aged 30 years or over with moderate airway obstruction owing to 
asthma or chronic bronchitis were selected for the study.11 Of the patients 
selected, 131 (53 with asthma and 78 with chronic bronchitis) completed the 
four-year follow up during which FEV, and peak flow measurements were made. 
The only medication allowed during the first two years of the study were the 
bronchodilators salbutamol or ipratropium bromide. At the end of the second 
year the annual rate of decline in FEV, was calculated for each patient by means 
of regression analysis. Patients were then divided into two groups according to 
the magnitude of their annual rate of decline. The first group comprised 48 
patients with an annual rate of decline in FEV, greater than 0.08 L year"1 (26 of 
whom had asthma). The second group comprised of 83 patients whose rate of 
decline in FEV, was less than 0.08 L year"1 (27 of whom had asthma) 
Beclomethasone dipropionate inhalations 400 ¿/g twice daily were added to the 
medication of all patients in the first group. No additional medication was given 
to patients in the second group. Both groups were monitored for a further two 
years. 
FEV, 
FEV, measurements were performed once every six months at the Department 
of Pulmonology, Dekkerswald, the Netherlands by two trained laboratory 
assistants. FEV, was measured using an integrating flow meter (Microspiro HI 
298R, Chest Corporation).12 Patients were instructed to refrain from 
bronchodilator therapy for at least eight hours before measurement. At each 
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measurement three forced expiratory manoeuvres were carried out. The 
difference between the highest and the lowest FEV, values had to be less than 
0.1 L; if this was not the case patients were asked to try again after a few 
minutes' rest. The FEV, of the attempt with the highest sum of FEV1 and forced 
vital capacity was retained for statistical analysis. All measurements were made 
during periods free of exacerbations. Exacerbations were defined according to 
Fletcher, modified according to Boman and colleagues.13 In total 9 half-yearly 
FEV, measurements per patient were available for analysis. 
Peak flow 
Peak flow was measured using the Assess" peak flow meter (Health scan 
products).14 All patients were given a peak flow meter and were taught to 
measure their own rate. Patients were asked to measure their peak flow once a 
week on the same day, three times in the morning, and to record all results in a 
diary card. All measurements were made before using bronchodilator 
medication. The patients technique in measuring and recording peak flow was 
checked at each visit to the lung function laboratory. The highest of the three 
peak flow measurements was considered for analysis. In total, 208 weekly peak 
flow measurements per patient were available for analysis. 
Patient symptoms and smoking history 
Patients recorded their symptoms on the Dutch version of a Medical Research 
Council respiratory symptoms questionnaire. The number of symptoms recorded 
were added together and presented as a score ranging from zero to eight. 
Smoking history was assessed in pack years, a pack being defined as 25 
cigarettes per day per year. 
Longitudinal correlation between FEV, and peak flow. 
Data of all 131 patients were analyzed for the first two years of the study. Five 
FEV, and 104 peak flow measurements per patient were considered for 
regression analysis. There were no missing values during the first two years. 
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The regression coefficient of the FEV, and of the peak flow were calculated and 
the former was then plotted against the latter for each patient. 
Data for the 83 patients in the group not receiving inhaled corticosteroids were 
analyzed for the four year of the study. Nine FEV, and 208 peak flow 
measurements per patient were considered for regression analysis. There was 
one missing FEV, value in the third year and three in the fourth year, thus, four 
patients had eight instead of nine FEV, measurements. In these cases the 
regression Coefficient was calculated for the available measurements. For each 
of the 83 patients the regression coefficient of FEV, was calculated and plotted 
against the regression coefficient of the peak flow. 
The cross-sectional correlation between FEV1 and peak flow. 
FEV, was measured on nine occasions. Nine corresponding peak flow values 
were obtained by calculating the mean of five consecutive weekly peak flow 
values for each FEV, value (the third peak flow value corresponded with the 
week of the FEV, measurement). The mean FEV, and mean peak flow values for 
patients in the first group (that is, patients who received inhaled corticosteroids 
during the third and fourth years of the study) and patients in the second group 
(those who did not receive inhaled corticosteroids) were then plotted on a time 
scale. 
Patient characteristics associated with a high correlation between FEV, and peak 
flow. 
A correlation coefficient of 0.6 or greater between the slopes of a patient's FEV, 
and peak flow was defined as being a high correlation and a correlation 
coefficient of less than 0.6 was defined as being low. Various patient 
characteristics, for example age, symptom score, pack years of cigarettes, 
bronchial hyperresponsiveness and percentage airway reversibility, were 
analyzed to determine whether any patient characteristics were associated with 
a high correlation between FEV, and peak flow. 
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Statistical tests 
The difference in the distribution of nominal variables between patients who had 
a high or low correlation coefficient between their FEV, and peak flow was 
tested using the chi square test. Continuous variables were tested using the 
unpaired t-test. The Wilcoxon test was used to test the difference in patients' 
bronchial hyperresponsiveness. 
7.4 Results 
Longitudinal correlation between FEV1 and peak flow. 
Two-year follow up. The relationship between the regression coefficient of the 
FEV, and the peak flow for each of the 131 patients during the first two years 
of the study is shown in Figure 7.1. In total 88 patients (67.2%) of whom 36 
had asthma, showed a decrease in FEV, and 59 patients (45%), of whom 19 
had asthma, showed a decrease in peak flow during this period. Forty seven 
patients (35.9%), 16 of whom had asthma, showed a decrease in both FEV, 
and peak flow. Forty one patients (31.3%), 20 of whom had asthma showed a 
decrease in FEV, and an increase in peak flow. Twelve patients (9.2%), three of 
whom had asthma, showed an increase in FEV, and a decrease in peak flow. 
Thirty one patients (23.7%), 14 of whom had asthma, showed an increase in 
both rates. 
Four-year follow up. The relationship between the regression coefficients of the 
FEV, and of the peak flow for each of the 83 patients not receiving inhaled 
corticosteroids followed up over four years is shown in Figure 7.2. In total 71 
patients (85.5%) 17 of whom had asthma, showed a decrease in FEV, and 39 
patients (47.0%), of whom 13 had asthma, showed a decrease in peak flow 
during this period. Thirty five patients (42.2%), 10 of whom had asthma, 
showed a decrease in both FEV, and peak flow. Thirty six patients (43.3%), 
seven of whom had asthma, showed a decrease in FEV, and an increase in peak 
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flow. Four patients (4.8%), three of whom had asthma, showed an increase in 
FEV, and a decrease in peak flow. Eight patients (9.6%), seven of whom had 
asthma, showed an increase in both rates. 
Regression coefficient PEF 
-0.8 -0,4 0 0.4 
Regression coefficient FEV1 
0.8 
Figure 7 .1 : Regression coefficients of FEV, and PEF of each patient after two 
years monitoring (n = 131) 
Cross-sectional correlation between FEV1 and peak flow. 
The mean FEV, and peak flow values for the 48 patients in the first group and 
the 83 patients in the second group over the four years are shown in Figure 7.3. 
Patients in the first group showed a decline in FEV, of 0.16 L year"1 during the 
first two years of the study while peak flow remained stable. Patients FEV, and 
peak flow increased during the initial six months of treatment with inhaled 
corticosteroids (FEV, increased by 0.46 L year'1). Although FEV, decreased after 
this initial treatment effect (by 0.10 L year"1) peak flow remained stable. The 
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decline in FEV, during this period was 0.06 L year"1 less than the rate of decline 
before treatment with inhaled corticosteroids. FEV, of patients in the second 
group showed a progressive decline over the four years of the study while peak 
flow remained approximately the same. 
Regression coefficient PEF 
-
n«36 
n-35 
ι 
°п ^ЩЩн 
D 
A 
Δ 
> Δ 
Δ 
α
 Bronchitis Δ Asthma 
ι 
n - 8 
n - 4 
ι 
•0,8 -0,4 0 0.4 0.8 
Regression coefficient FEV1 
Figure 7.2: Regression coefficients of FEV, and PEF of each patient after four 
years monitoring (n = 83) 
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Figure 7.3: The mean FEV, and PEF during the four years 
Patient characteristics associated with a high correlation between FEV, and peak 
flow 
A total of 101 patients had a correlation coefficient of less than 0.6 between 
their FEV, and peak flow (low correlation group) and 30 patients had a 
correlation coefficient of 0.6 or greater (high correlation group). No patient 
characteristics were found to be associated with a high correlation between 
FEV, and peak flow (Table 7.1). Patient characteristics that were asthma related 
such as bronchial hyperresponsiveness, reversibility of airway obstruction, atopy 
and a diagnosis asthma, were associated with a high correlation between FEV, 
and peak flow, but none of the characteristics showed a significant difference 
between the two groups. 
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Table 7.1: 
Patient characteristics associated with a high or low correlation between FEV, 
and peak expiratory flow rate IPEFR) 
Patient characteristic· Low correlation (r < 0.6) Good correlation Ir > 0.6) 
Number of patients 
Age (years) 
Packyears 
FEV, (L sec1) 
FEV, (%predicted) 
PCs, (mg ml"1) 
peak flow (L min'1) 
Reversibility (%) 
Symptom score 
Sex (male) 
Smoker (%) 
Atopy (%) 
Asthma (%) 
101 
52 
17 
2.4 
76 
4 
553 
16 
5 
59 
56 
24 
36 
30 
50 
15 
2.2 
73 
2 
525 
22 
5 
13 
40 
33 
57 
7.5 Discussion 
This study failed to demonstrate a long-term correlation between FEV, and peak 
flow in patients with moderate asthma or chronic bronchitis. The majority of 
patients showed a long-term decline in FEV, while only a few showed a decline 
in peak flow. The percentage of patients showing a decline in FEV, increased 
over time. There was, however, only a marginal increase in the percentage of 
patients showing a decline in peak flow. The short term effect of inhaled 
corticosteroid treatment on the level of FEV, and peak flow during the first half 
of the third year showed a possible correlation on a group basis. Although 
asthma patients showed a high correlation between peak flow and FEV,, no 
patient characteristics were found that could predict a high correlation between 
the two rates. Hence it can be concluded that, unlike the FEV,, the peak flow is 
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not capable of detecting the annual decline in lung function in adults with 
moderate asthma or chronic bronchitis. 
The general practice management of asthma, including self-management, is 
based on daily peak flow measurements, whereby the "traffic light" system of 
colour-coded peak flow measurement zones provides the patient with an easy to 
understand method of maintaining the lung function at the highest possible 
level.1 The effect of appropriate medical intervention can also be demonstrated 
by short-term monitoring of the peak flow: the present study showed a rise in 
peak flow during intervention with inhaled corticosteroids. Peak flow has also 
been shown to be a reliable measure of the reversibility of airways obstruction.4 
Other investigations have shown a good short-term relationship between peak 
flow and FEV,.10 Peak flow can, therefore, be considered as a reliable parameter 
for monitoring the short-term changes in lung function in patients with asthma 
or chronic bronchitis. 
FEV, provides an integrated index of the maximum flow during ±75% of the 
expiratory flow-volume curve.16 Peak flow mainly reflects the conductance in 
the central airways and is responsible for only the initial part of the flow-volume 
curve. Both FEV, and peak flow are known to be effort-dependent and relatively 
insensitive to minor changes in the calibre of peripheral airways. The time span 
within which the two parameters are measured is therefore a possible 
explanation for the difference in sensitivity to minor changes in maximum flow 
of air. 
No long-term correlation was found to exist between peak flow and FEV,. The 
consequence of this fact is of clinical importance. A patient with a stable peak 
flow, measured during consecutive consultations, can have a rapid decline in 
FEV, which can proceed unnoticed if the FEV, is not assessed. Peak flow is 
therefore not suitable for detecting patients at an early stage who have a rapid 
decline in lung function. Since early detection and treatment of patients with 
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asthma or chronic bronchitis is the only way to improve the long-term prognosis 
of these patients, general practitioners could consider using a spirometer for 
monitoring lung function in adults. Modern portable spirometers are inexpensive 
and easy to use. In the near future much cheaper and more accurate 
spirometers are expected. Almost all portable spirometers also measure peak 
flow. Such an instrument would allow general practitioners to continue 
measuring the peak flow in order to assess short-term changes in lung function 
while providing an important means for monitoring FEV, for the assessment of 
the long-term changes in FEV,. 
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8 The effectiveness of treatment of subjects with 
obstructive airways disease detected by means of 
screening the general population 
8.1 Abstract 
Background: Secondary prevention of diseases with airways obstruction by 
means of early detection and treatment now seems a useful option for improving 
the long term prognosis of these patients. Before such measures are 
implemented in practice it is important to know whether treatment at an early 
stage is effective. 
Objective: To investigate the effect of inhaled steroids on lung function, 
bronchial hyperresponsiveness and respiratory symptoms in subjects with 
obstructive airways disease who were detected by screening a sample of the 
general adult population. 
Patients: Subjects with no prior diagnosis of asthma or COPD, but with 
respiratory symptoms and impaired lung function (FEV, < reference value minus 
2 standard deviations on at least two separate assessments 3 months apart) or 
a high bronchial hyperresponsiveness (PC20 less than 2 mg/ml) combined with a 
high reversibility of the airway obstruction (>15% of the reference value) were 
considered for this study. 
Design: A randomized, double-blind, placebo controlled one-year study to assess 
the effect of inhaled-steroids on respiratory symptoms and lung function. 
Methods: 54 subjects out of a random population of 1155 subjects were found 
to be eligible for the study. Of these, 31 subjects participated in the trial, six 
had to be retired for medical or organisational reasons and 17 refused 
participation. The intervention was with Fluticasone Propionate 250 //g B.D. 
Participants were randomized into either an intervention group (n = 15) or a 
placebo group (n = 16). FEV, and PC20 were monitored once every three months 
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during one year. Symptoms and PEF were monitored once every week. 
Outcome variables: FEV,, PCjo, respiratory symptoms, peak flow and 
exacerbations. 
Results: The study showed that 7% of the general adult population with no prior 
diagnosis of asthma or COPD had an undiagnosed obstructive airways disease. 
These subjects were characterized by a reduced FEV, (72% of the predicted 
FEV,), an increased hyperresponsiveness (PC20 was 2.46 mg/ml histamine) and 
the presence of symptoms. After treatment with steroids, the FEV, and PC» 
showed a significant improvement of respectively 76 ml (p = 0.02) and 1.4 
doubling dose of histamine (p = 0.002). The number of exacerbations was five-
fold less during steroid treatment (0.27 versus 1.3 exacerbation per patient per 
year), however, this difference was not significant (p = 0.18). There was no 
significant improvement in symptoms or peak flow. 
Conclusions: The deteriorated lung function and increased bronchial 
hyperresponsiveness of subjects with obstructive airways disease, detected by 
screening the general population can be improved by steroid treatment. This 
study also indicates the problems that can be expected in convincing such 
subjects of a probable health risk when they are not treated. 
8.2 Introduction 
Current concepts on management of asthma1,2 and COPD3 are based on 
prevention and control of the disease. Primary prevention by avoiding triggers 
such as allergens, viral infections, occupational pollutants and cigarette smoke 
are in practice not always possible. Therefore more consideration should be 
given to secondary prevention. This calls for the possibility of detecting and 
treating subjects at an early stage of the disease. The goal of secondary 
prevention would be to limit respiratory morbidity and functional impairments in 
the long run. 
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Respiratory symptoms have been reported to show a poor correlation with the 
lung function.4 Therefore it is reasonable to assume the existence of subjects 
with objective abnormalities in lung function who may not perceive (serious) 
symptoms properly and therefore remain unknown to the general practitioner 
(GP). Such subjects can only be identified by means of active screening 
methods. Little is known of the prevalence or seriousness of this condition or 
the possibility for treatment under these circumstances. On the other hand, 
various studies have demonstrated the possibility of reducing symptoms and 
improving lung function indices by treating patients already diagnosed as having 
asthma, with inhaled corticosteroids.6-6 These drugs are considered an effective 
first-line of treatment for inflammation which is commonly seen in 
asthma.1·2·789·10 
It is not yet known whether treatment is also effective in subjects with objective 
lung function abnormalities who have been detected by means of screening. 
There is some evidence of a reluctance of patients with mild symptoms to be 
treated.11 Compliance might therefore be a problem in subjects found on 
screening. If these subjects can be treated effectively then secondary prevention 
by means of active detection and early treatment can be considered a possible 
option for current practice in order to improve their long-term prognosis. 
The aim of this study was to investigate the efficacy of inhaled steroids on lung 
function and bronchial hyperresponsiveness and respiratory symptoms in 
subjects detected by screening the general population12. These subjects were 
characterized as having moderate to serious lung function abnormalities with no 
apparent discomfort and therefore were largely unknown to the GP. 
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8.3 Methods 
Design: 
A randomized, double-blind, placebo controlled, parallel-group study was 
performed during a period of one year. Subjects who gave written informed 
consent after being fully informed of the trial-protocol were randomly allocated 
into one of two groups; a) Intervention group: Fluticasone Propionate 250 pg 
BD; or b) Control group; placebo BD. Both steroid and placebo were 
administered by blinded, metered dose inhalers of 125 ¿/g per puff. This study 
was approved by the Ethics Committee of the University of Nijmegen. 
Patient selection: 
Subjects were selected from a sample of the general population by means of a 
two-phase screening. Details of this first phase have been described 
elsewhere.12 Relevant results are summarized here. 
Phase-1: To detect subjects with signs and symptoms of asthma or COPD in the 
general population. 
A random sample of 1749 adults (age 25-70 years) in the Nijmegen region were 
invited, of which 1155 subjects were assessed for respiratory symptoms, forced 
expiratory volume in one second (FEV,) and the degree of reversibility. None of 
the 1155 subjects had a prior history of asthma or COPD or were using 
corticosteroids regularly. There was no selection bias between the subjects who 
participated in phase-1 and those who refused to take part.12 Subjects were 
eligible for phase-2 if at least one of the following criteria was positive: 
a) respiratory symptoms assessed by means of a Dutch version of the MRC 
questionnaire4-13 and/or 
b) FEV, less than the reference value minus 1.64 standard deviation and/or 
c) percentage of reversibility greater than 15% of the reference value after 800 
//g salbutamol. 
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Six hundred and four (52%) subjects fulfilled at least one of these criteria and 
384 (64%) of them volunteered to take part in the second phase of this study. 
There was no selection bias between the 384 subjects who were willing to 
participate in phase-2 and the 220 who refused to participate1 2. 
Phase-2: To assess the persistence of impaired lungfunction and bronchial 
hyperresponsiveness (BHR). 
This phase consisted of three measurements each three months apart consisting 
of an assessment of respiratory symptoms, FEV,, percentage reversibility of 
airway obstruction. Bronchial hyperresponsiveness was assessed by means of 
the histamine provocation test (PC^) during the first measurement. Patient 
characteristics such as smoking history and allergy were also assessed during 
this visit. Subjects with an objective impairment in lung function or BHR were 
selected for the intervention study if they fulfilled at least one of the following 
inclusion criteria: 
1 FEV, less than the reference value minus two times the standard deviation on 
at least t w o out of four measurements. 
2 PCJO less than 2 mg/ml and/or a reversibility of FEV, higher than 15% of the 
reference value after administration of 800 μg salbutamol. 
In total 54 subjects fulfilled the above criteria and were eligible to take part in 
the trial. 
The schedule of measurements 
Subjects visited both their GP and the hospital lung function laboratory at the 
start of the trial and once every three months, during a total period of 12 
months. All subjects recorded their morning and evening peak f low and 
respiratory symptoms once every week in a diary. The GP evaluated the 
subject's medical status, respiratory symptoms and the presence of any adverse 
events during each visit. The lung function and BHR were assessed during each 
visit at the hospital lung function laboratory. 
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Outcome variables 
1. FEV, and degree of reversibility of the airway obstruction: 
The FEV, was measured at the hospital lung function laboratory by means of a 
portable Microspiro HI-29814 (Chest corporation, Tokyo, Japan). Each subject 
performed three forced expiratory manoeuvres from maximum inspiration and 
the FEV, of the manoeuvre with the highest value sum of FEV, and FVC was 
chosen.16 
The degree of reversibility was defined as the change in FEV, 15 minutes after 
the administration of 800 MQ salbutamol and expressed as a percentage of the 
predicted value.10 
2. Histamine provocation test (PC20). 
This was assessed according to the method described by Cockcroft et al.1 7 
Subjects were not tested if their baseline FEV, was less than one Litre or less 
than 50% of the reference value. The provocational concentration of histamine 
causing a 20% fall in FEV, from the base-line value (PC20) was calculated by 
linear interpolation of the difference in FEV, versus 2log[dose histamine] plot. 
Subjects showing a 20% drop in FEV, after the administration of buffered saline 
were considered as having a PC20 of 0.015, which is half the lowest 
concentration histamine used. 
3. Respiratory symptoms. 
The weekly diary was used to assess the severity of the three following 
symptoms: a) wheeze, b) shortness of breath, c) cough d) phlegm production. 
Subjects scored the severity of each symptom on an integer scale of 0-3. The 
total symptom score was calculated by adding the score of each symptom 
(range 0-12). 
4. Number of exacerbations. 
An exacerbation was defined by the presence of at least two of the following 3 
items during a period of at least two consecutive weeks: a) aggravated cough, 
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shortness of breath, wheeze; b) a change in the colour of phlegm; c) increased 
need for bronchodilators. Information was collected from two sources; 1 ) diary 
cards of the subjects and 2) Record forms of the GP. Any episode reported in 
either of the sources was considered an exacerbation. The data were carefully 
analyzed to avoid double counting of the same exacerbation that had been 
reported in both sources. 
5. Peak Expiratory Flow (PEF) and diurnal variation. 
The PEF was measured by the subjects by means of a Mini-Wright Peak flow 
meter once every week on the same day, at approximately the same time. 
Subjects measured the PEF three times in the morning and three times in the 
evening and recorded this in their weekly diary. The highest of the three 
measurements was considered for analysis. All subjects were trained in 
measuring their own peak flow. The subject's technique was checked during 
each three-monthly visit to the hospital lung function laboratory. 
The diurnal variation of peak flow (DVPEF) was calculated by means of the 
following formula. 
DVPEF = [(Highest-lowestl/highest] X 100% 
Data analysis. 
Patient characteristics of participants versus non-participants and those who 
completed the trial versus drop-outs were tested by means of unpaired t-tests, 
except for nominal variables which were tested using chi-square test and PCM 
which was tested by means of the Mann-Whitney U test. An intention to treat 
analysis was performed with all randomized subjects. All available data on drop-
outs who received study medication after randomization were included in the 
analysis. The difference in outcome variables between each point of 
measurement and the baseline measurement was considered for analysis. The 
total medication effect, time effect and interaction effect (steroid - placebo) for 
FEVV PC», PEF was assessed by means of repeated measurements ANOVA 
(statistical programme BMDP). The symptom score (average of three months) 
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and the number of exacerbations were tested by means of the Mann-Whitney Li-
test for not normally distributed variables. We considered differences with a p-
value less than 0.05 as statistically significant. 
8.4 Results: 
Fifty-four of the 384 subjects (phase-2) had persistent signs/symptoms or BHR. 
The 54 selected fulfilled these criteria as follows; 44 subjects fulfilled criterion-1 
(symptoms and a persistently low FEV,), six subjects fulfilled criterion-2 
(symptoms and a high bronchial responsiveness combined with a high 
percentage of reversibility) and four subjects fulfilled both criteria. Since no 
selection bias was found between the 384 subjects who were willing to 
participate in the second phase and the 220 who refused to participate, the 
eligible subjects could be considered representative for the total group of 604. 
This means 7% of the sample of 1155 adults with no prior diagnosis of 
asthma/COPD in the general population, consist of a previously undiagnosed 
obstructive airways disease with an indication for treatment. The 54 subjects 
had a significantly lower FEV,, %FEV, VC and PC^ and they had smoked more 
in comparison to the remaining 330 subjects (Table-8.1). 
Of these 54 subjects, 48 were invited for this trial. Three subjects were not 
entered in the trial due to organizational reasons: two were not detected within 
the inclusion period and one did not return the letter of consent within this 
period. Three other subjects were not entered due to medical reasons: two due 
to pregnancy and one due to the use of ß-blocking medication. Of the 48 
subjects invited, 31 (65%) started the trial and 17 (35%) refused to participate. 
The following reasons were recorded for not participating: lack of 
time/motivation (11 subjects), somatic/psychosocial reasons (five subjects) and 
religious reasons ( one subject). These 'official' reasons for not participating 
were frequently accompanied by mentioning that in their opinion they were not 
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ill and therefore were unwilling to take medication. We compared the 
characteristics of the 31 participants and the 23 non-participants and found no 
statistically significant difference (Table 2). 
Table 8.1 
Patient characteristics of subjects selected for the trial compared with the remaining subjects. 
Patient 
characteristics 
Age (years) 
VC (ml) 
FEV, (ml) 
FEV, % predicted 
Reversibility) %) 
Packyears 
Symptom score 
PC» 
Allergy 1%) 
Selected for the trial 
(n = 64) 
44(12) 
3336 (843) 
2315 (520) 
70.6(10.2) 
6.2 (8.7) 
13.3(13.9) 
1.9(1.5) 
0.8 (3.4) 
44.4 
Not selected for the trial 
(n = 330) 
43(11) 
4115(1043) 
3238 (753) 
96.5(13.2) 
4.0(4.1) 
8.2(10.4) 
1.3 (1.2) 
3.3 (2.4) 
35.8 
Ρ value 
0.3 
0.0000 
0.0001 
0.0001 
0.06 
0.01 
0.007 
0.0001 
0.2 
Of the 31 randomized subjects 15 received steroids and 16 placebo (Table-8.3). 
There were no significant differences between the characteristics of the two 
groups except for age (lower in placebo group) and allergy (less frequent in 
placebo group). Of the 31 subjects nine did not complete the trial due to the 
following reasons (Table-8.2): two due to organisational reasons (moved to 
another area), five due to secondary lack of motivation and two due to other 
medical reasons (heart disease and exacerbation of M.Hodgkin). Of these nine, 
five used steroids and four placebo. None of these subjects stopped because of 
adverse effects of medication. 
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Table 8.2 
Participants and drop-outs. Standard deviations for the different subject characteristics have 
been given within brackets. PC„ is presented as a geometric mean. 
Patient 
Characteristics 
Number 
Sex (M/F) 
Age (years) 
Height (m) 
FEV, (ml) 
%FEV, 
FVC (ml) 
%Fteversib¡lity 
PCS0 
Packyears 
Smokers (number) 
Symptom score 
Allergic (number) 
Eligible for the trial (n = 54) 
Participants 
31 
11/20 
46(11) 
1.7(0.1) 
2313 1563) 
71.7(13.5) 
3389 (780) 
7.1 (5.3) 
2.46 
14.5 (11.4) 
19 
1.7(1.4) 
15 
Non-participants 
23 
9/14 
44 (14) 
1.7(0.1) 
2350 (640) 
71.4(14.2) 
3340(1030) 
9.0 (8.6) 
1.07 
11.6(16.8) 
8 
1.6(1.3) 
9 
Started the trial (n = 
Finished trial 
22 
10/12 · 
48.0(11.9) 
1.7(0.1) 
2342 (579) 
71.6(13.6) 
3539 (792) 
6.8 (5.2) 
3.25 
16.5(11.8) 
13 
1.4 (1.4) 
10 
 31) 
Drop-outs 
9 
1/8 
39.8 (9.5) 
1.7(0.1) 
2243 (548) 
71.8(14.1) 
3022 (651) 
7.9 (5.7) 
1.23 
9.6 (9.4) 
6 
2.3 (0.9) 
5 
= P<0.05 
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Table 8.3 
Comparison of the base-tine characteristics of the intervention (steroid/ group and the placebo 
group. Standard deviations for the different subject characteristics have been given within 
brackets. PC„ has been presented as a geometric mean. 
Subject characteristic 
Number 
Sex (M/F) 
Age (years) 
Height (meters) 
FEV, (ml) 
FEV, % predicted 
FVC (ml) 
%Reversibility 
PC„ 
Packyears 
Smokers (number) 
Symptom score 
Steroids 
15 
7/8 
51 (9) · 
1.7(0.1) 
2208 (558) 
70.9(17.0) 
3363 (659) 
7.3 (5.0) 
2.14 
16.9(11.7) 
9 
2.0(1.5) 
Placebo 
16 
4/12 
41 (11) 
1.7(0.1) 
2412(567) 
72.3 (9.6) 
3413 (901) 
6.9 (5.7) 
2.64 
12.2(11.1) 
10 
1.4(1.2) 
• =p<0.05 
FEV, 
Figure-8.1 shows the change in pre/post-bronchodilator FEV, from baseline for 
each point of measurement. Repeated measurements analysis for the pre-
bronchodilator FEV, showed that the mean difference (steroid - placebo) of the 
change from base-line during the treatment period (overall medication effect) 
was 76 ml (p = 0.02). A time effect was found (p = 0.02). The same analysis for 
the post-bronchodilator FEV, showed an overall medication effect of 57.7 ml 
(p = 0.05) and time effect (p = 0.03). The cross-sectional differences for each 
measurement point value are shown in Table-8.4. 
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Pre-/Post- bronchodilator FEV1 (ml) 
300 
200 
100 
-100 
-200 
-300 
•и-Steroid FEV1-pre о Placebo FEVI-pre 
О Steroid FEV 1-post О Placebo FEV1-post 
12 
Time (months) 
Figure 8.1: The mean difference in FEV, from baseline for each point of 
measurement. 
PC20 
Figure-8.2 shows the change in PC20 from baseline for each point of 
measurement. Repeated measurements analysis showed that the overall 
medication effect was 1.4 doubling dose (p = 0.002). This difference did not 
significantly depend on the point of measurement in time (p = 0.6). The cross-
sectional values are shown in Table-8.4. 
Peak flow (PEF) and the Diurnal variation in PEF (DVPEF). 
Table-8.5 shows the change in PEF from baseline for each point of 
measurement. Table 5 also shows the change in diurnal variation in PEF from 
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baseline for each point of measurement. Repeated measurements showed for 
both variables that there was no significant medication effect. 
Respiratory symptoms: 
Table-8.5 shows the difference in the average symptom score at each point of 
measurement in comparison to the base-line value at the start of the trial. No 
significant differences were found between the two groups at any point of 
measurement (Mann-Whitney U test). 
PC20 (doubling dose histamine) 
-1 
-2 
О Steroid PC20 
"°" Placebo PC20 
% 
0 3 6 9 12 
Time (months) 
Figure 8.2: The mean difference in PC20 from baseline for each point of 
measurement. 
Number of exacerbations 
In total 25 exacerbations were recorded during the trial: four in the steroid group 
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and 21 ¡η the placebo group. These exacerbations concerned three of the 15 
subjects in the steroid group and all 16 subjects in the placebo group. The 
number of exacerbations per subject per year for the intervention group was 
therefore five-fold less compared to the control group (0.27 versus 1.3). 
However, this difference was not statistically significant (p = 0.18). 
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8.5 Discussion 
This study investigated the efficacy of early treatment with inhaled steroids 
(fluticasone propionate) in subjects with an obstructive airways disease who 
were previously unknown to the GP. No clinical data are available to date, to 
decide whether such subjects detected by means of screening can benefit by 
treatment. In order to study the efficacy of treatment on such subjects it was 
necessary to compare an intervention group with a placebo group. This gives 
rise to the question whether it is ethical to treat subjects with such a reduced 
lung function and increased BHR with a placebo. It was considered ethical to 
offer these subjects placebo medication during a limited period: none of these 
subjects had ever sought any medical care for their respiratory problems, and 
placebo treatment therefore would only be a continuation of their current, 
untreated status. Subjects were completely informed about their medical status 
and they were free to stop the trial at any stage to receive regular medical 
treatment. 
We investigated the efficacy of inhaled steroids in treating a unique group of 
subjects. These subjects were characterized by a reduced lung function, an 
increased BHR and with (relatively few) symptoms. The analysis assessed the 
difference in medication-related effects to measurement points. A significant 
increase in average FEV, and PC^ was seen in subjects using steroids in 
contrast to subjects using placebo medication. The difference in magnitude for 
the above two variables was visible during the first three months and remained 
stable during the remaining nine months of the trial. However, there was no 
significant decrease in the average number of respiratory symptoms or an 
improvement in peak flow in the intervention group in comparison to the control 
group. The lower number of exacerbations in the steroid group, relevant from a 
clinical point of view, was not statistically significant. 
Haahtela et al6 reported that steroid therapy caused an improvement in 
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respiratory symptoms, PEF and bronchial responsiveness in newly identified 
patients with mild asthma. The beneficial effect on bronchial responsiveness 
was seen after six weeks of treatment and the difference was sustained 
throughout the entire study period of two years. However the FEV, showed no 
significant improvement. In that study patients had a %FEV, of predicted value 
of 88% at the start of the study. In our study the steroid effect on FEV, was 
significantly higher. The fact that subjects in our study had a greater deficit in 
FEV, at the start may provide a possible explanation for the difference between 
both studies. In our study there was more room for improvement in FEV,. 
Dompeling et al. have also reported a significant improvement in FEV, and BHR 
in patients with asthma and COPD with a deficit in FEV, who were treated with 
beclomethasone." 
The reduction in symptoms seen in both above mentioned studies66 is in 
contrast to our results. This contrast could also be attributed to the difference in 
study populations. Haahtela et al6 and Dompeling et al" recruited patients who 
had consulted their general practitioner or chest physician for respiratory 
symptoms and had already been diagnosed as having asthma or COPD. In 
contrast the present study recruited subjects from a screening and symptom 
perception and presentation to the GP might have played a much less important 
role.12 Consequently, there was less room for an improvement in symptoms. A 
reduced perception of symptoms, in particular of shortness of breath18 might be 
a critical issue in these apparently 'a-symptomatic' subjects. The number of 
exacerbations recorded during the total period of one year was higher in the 
control group, although this difference did not reach statistical significance, it 
seems clinically relevant. 
Because of unbalance after randomisation the average age of the intervention 
group was significantly higher than the control group. The number of pack years 
smoked was also higher in the intervention group. This might have contributed 
to an underestimation of the medication effect19. On the other hand the 
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intervention group consisted of a higher percentage of allergic subjects. This can 
be considered to enhance the medication effect of this study.1' 
An important observation was made during this study regarding the willingness 
to accept medication. Although all subjects were fully informed about their 
medical status a large proportion either refused to take part in this study or 
stopped prematurely due to reasons which in all probability point to lack of 
motivation. It is interesting to note that subjects were willing to take part in the 
screening and in the three base-line assessments, but when possible medication 
became an issue they refused further participation. The possibility of being 
allocated placebo treatment might have influenced their decision, but this is in 
our view not very likely in the light of the fact that all subjects who refused to 
take part did not ask for medical treatment after their refusal. Only a small 
proportion of the drop-outs were caused by factors beyond the control of the 
eligible subjects (medical reasons, moving to another area). Less than half of the 
subjects detected with obstructive airways disease were willing to undergo 
treatment. The willingness to participate was dramatically lower than in previous 
studies on the same disease in the same region and using a comparable 
intervention49. In our view this is a remarkable finding and is important when 
considering the possibility of screening the general population on asthma or 
COPD. 
The costs of active detection and treatment is also an important factor which 
must be taken into consideration. Costs caused by absenteeism from work due 
to respiratory diseases should be weighed against the cost of active screening 
of such individuals and other negative effects of screening such as 
overdiagnosis. Further studies on cost-effectiveness of active detection and 
treatment in comparison to currently employed methods on diagnosis and 
therapy are necessary. 
We found that 7% of the adult general practice population screened, had 
obstructive airways disease who had never been diagnosed or treated for 
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asthma or COPD prior to the screening. We conclude that it is possible to treat 
subjects with a mild disease, with an impaired lung function and increased BHR 
effectively with steroids. This is an important finding for propagating secondary 
prevention by active detection and treatment in an early stage, before a clinical 
diagnosis of asthma or COPD has been made in routine medical care. 
Knowledge on whether subjects with a serious deficit in lung function can be 
treated effectively is mandatory before active screening for such patients can be 
implemented in the general population. Our study therefore provides important 
information regarding this subject. The other important conclusion is the 
difficulty of regular treatment and follow-up of these subjects. If our results can 
be extrapolated to routine medical care, about a third (or more) of the eligible 
patients may not accept treatment and take the risk (after being fully informed) 
of undertreatment. The success of screening will be clearly diminished if this is 
the general attitude of these subjects towards treatment. This would be the 
biggest challenge for effective treatment (preventive treatment) of obstructive 
airways disease at an early stage. It reinforces the need to provide effective 
education and follow-up care. Only then can screening/case finding be promoted 
with the prospect of a successful outcome. 
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9 Summary 
The unregistered morbidity with regard to obstructive airway diseases (OAD) 
was the central topic of this thesis. The existence of individuals in the general 
population with signs and symptoms of OAD who have not been diagnosed as 
such may indicate a possible shortcoming in current medical practice. Although 
there is growing consensus on diagnosis and therapy of asthma and COPD, this 
knowledge can only be applied to the registered morbidity. The unregistered 
morbidity of today may eventually lead to problems in the future. This thesis 
focused on the possibility of actively detecting individuals with a mild OAD, at 
an early stage by means of screening the general population. The aim of active 
detection is to enable the implementation of guidelines on diagnosis and therapy 
of asthma and COPD to all individuals with a mild, non-manifest disease, in 
order to reduce morbidity, mortality and to improve their long-term prognosis in 
the future. 
Chapter 2 can be considered as the basic study of this thesis. In this chapter we 
assessed the extent of the problem of undiagnosed OAD. We compared the 
results of our screening in 1992 with that of a similar screening in the same 
region conducted in 1977. A cross-sectional comparison of the two surveys 
showed that in 1992 approximately 65% of the subjects detected with signs of 
OAD were not known to the respective general practitioners (GP's). The 
majority of these subjects were found to have a mild form of the disease. OAD 
was defined according to epidemiological criteria used in 1977 in order to 
facilitate comparison between the two surveys. According to current criteria 
these subjects could be defined as having a very mild, sub-clinical form of the 
disease. This study also confirms the increase in prevalence of OAD reported in 
the literature. This study showed that the increase cannot be exclusively 
ascribed to increased awareness of the disease by doctors and patients, 
therefore an increase in airway pathology may also play a role. It should be 
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emphasized that predominantly very mild cases were the cause of this increase 
in prevalence. It can be concluded that unregistered morbidity with regard to 
OAD, consists of approximately 65% of subjects with a very mild form of the 
disease. This introduces the option of screening the general population, in order 
to enable secondary prevention of OAD. 
In Chapter-3 we investigated the influence of perception of shortness of breath 
and psychological characteristics as possible reasons for the existence of 
unregistered OAD. Of the 1155 adults screened, 439 had at some stage 
experienced shortness of breath. Of these subjects only 28% had ever 
consulted their GP for this. Almost twice as many subjects with a good 
perception of shortness of breath consulted the GP in comparison to those with 
a poor perception. The most probable psychological factors had no significant 
influence on the patient's choice to consult the GP for shortness of breath. On 
the basis of these results it was concluded that underreporting of symptoms is a 
major factor contributing to unregistered morbidity in the population. A lack of 
proper perception of dyspnoea may be responsible for not consulting the GP. 
Chapter-4 can be considered as the main study of this thesis. We investigated 
the efficacy of screening the general population in order to detect unregistered 
morbidity. We showed that the screening-criteria advocated in this study were 
suitable in actively detecting subjects with a mild but persistently reduced FEV,. 
This persistently low FEV, may be the result of a rapid decline in lung function 
during the previous years, or it may be the result of a lower plateau reached 
during early adulthood. This study also shows that subjects with a rapid decline 
cannot be distinguished from those with a normal decline by means of this 
screening test. This leads to two conclusions; firstly, screening the general 
population with a simple test (respiratory symptoms questionnaire and 
spirometry) is an effective method for detecting subjects with a mild but 
persistently reduced lung function. Secondly, subjects with a rapid decline in 
lung function cannot be detected by means of a screening test. They may 
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require lung function monitoring in order to assess the decline accurately. 
Chapters 5,6 and 7 can be regarded as a scrutiny of instruments available for 
the GP in order to detect subjects with an indication for treatment at an early 
stage. 
In Chapter-5 we studied the clinical relevance of questions on bronchial 
hyperresponsiveness (BHR) and allergy in detecting subjects with an indication 
for treatment. It was shown that a negative response to questions on either BHR 
or allergy indicated in the majority of cases the absence of any form of OAD 
that may need treatment. A positive response to any of these questions 
appeared to have a limited clinical relevance, and would require additional 
diagnostic tests. Therefore questions regarding BHR and allergy would help the 
GP to select patients who may need further assessment in lung function 
laboratories (PC20 and allergy tests). The above information may eliminate the 
uncertainty a GP could have in requesting further diagnostic tests, specially 
when dealing with patients with no clear respiratory abnormalities. 
In Chapter-6 we investigated the effect of the frequency of FEV, measurements 
and the necessary duration of the observation period in order to detect subjects 
with an increased rate of decline in lung function. This was done by means of a 
statistical model. We found that subjects with a rate of decline in FEV, greater 
than ±160 ml/year, assessed during a period of one year would in the vast 
majority of cases have an abnormal decline in lung function. However, this is 
not true for subjects with a lesser rate of decline, for example 100 ml/year. 
They may or may not have a rapid decline in lung function as there is a high 
percentage of false positive results. Therefore an observation period of at least 
two years is needed to diagnose an abnormality in such subjects. These findings 
were consistent with the results in chapter-4. Therefore initiating treatment on 
the basis of a rapid rate of decline ( ± 80 ml/year) assessed during a period of 
one year cannot be justified. In such cases either the follow-up period should be 
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extended by another year or auxiliary data such as BHR and reversibility should 
be taken into consideration. We concluded that FEV, assessments during a 
period of two years with a frequency of once every 3 or 6 months Is sufficient 
for the reliable diagnosis of subjects with a moderate to severe increase In the 
rate of decline. It should be emphasized that these individuals should be 
detected as early as possible as they have the most to benefit by early 
treatment. 
In Chapter-7 we investigated the value of longitudinal peak flow data. Peak flow 
is commonly used in general practice and is a valuable parameter in the cross-
sectional evaluation of lung function. However, we found no long-term 
correlation between peak flow and FEV,, which is presently considered the gold 
standard in the evaluation of lung function. Therefore peak flow cannot be used 
to detect patients with a rapid decline in lung function as it is not a good 
Indicator of the decline. For this purpose it is advisable to implement the use of 
portable spirometers in general practice, which also measure the FEV,. 
Chapter-8 shows the effect of treating subjects with a mild disease, detected by 
means of screening the general population. Active detection of subjects with a 
mild disease would be a waste of time if no proper treatment was at hand. 
Although it is commonly known that inhaled corticosteroids have the ability for 
(temporarily) elevating FEV, in patients with a manifest asthma, literature is void 
of experience in treating subjects who are actively detected by means of 
screening. Chapter 8 presents a prospective, placebo controlled study on the 
efficacy of inhaled steroids in treating subjects with a mild OAD, detected by 
means of screening the general population. These subjects were characterized 
by the presence of respiratory symptoms, a reduced FEV, (72% of the predicted 
FEV,) and an increased hyperresponsiveness (PC^, was 2.46 mg/ml histamine). 
After treatment with inhaled steroids, FEV, and PC20 showed a significant 
improvement of respectively 76 ml (p=0.02) and 1.4 doubling dose of 
histamine (p = 0.002). The number of exacerbations was five fold lower in the 
145 
Active detection of OAD 
steroid group in comparison to the placebo group. However, this difference was 
not statistically significant due to the low number of participants. There was no 
significant improvement in symptoms or peak flow. It can therefore be 
concluded that the deteriorated lung function and Increased BHR of subjects 
with an OAD, detected by screening the general population can be improved by 
anti-inflammatory treatment. 
Conclusion 
There is a need for active detection of patients with OAD and the existing 
methods of detection and follow up need refining. Patients with mild OAD can 
be detected at an early stage by means of screening the general population. 
Such patients can be treated effectively with inhaled corticosteroids. 
Recommendations 
1 Screening the population was shown to be an effective method for 
detecting subjects with a mild OAD at an early stage. However it is 
not feasible in general practice to screen each individual in the 
population. Therefore attention should be paid to active case-finding in 
persons with known risk factors. Patients consulting the GP, 
independant of the reason for consultation, should be given a 
respiratory symptoms questionnaire for self administration while 
waiting for the appointment. This questionnaire should include 
information regarding cough, phglem production, dyspnoea, wheeze, 
allergy, non-specific bronchial hyperresponsiveness, positive family 
history and smoking habits. 
2 It is advisable to assess the FEV, in all persons with any positive 
questionnaire items. Spirometry should be performed by individuals 
with prior training, with the use of reliable, calibrated equipment 
146 
Chapter 9 
according to standard procedures. This is essential as the FEV, shows 
a great variability within individuals. 
3 Subjects should be assessed again three to six months later in order 
to confirm the preliminary findings. In this manner it is possible to 
identify and treat those with a persistently impaired lung function 
without any further delay. 
4 It is advisable to use portable spirometers for measuring the FEV, in 
general practice. Such spirometers are accurate, easy to use and even 
more importantly, affordable. Since most practices at present are 
computerized, more thought could be given to investing in lung 
function soft ware. 
5 More emphasis regarding active case finding should be given during 
the GP training scheme. It is important that the GP is convinced of the 
value of active case finding. 
6 An attempt should be made to reduce underpresentation of 
symptoms. Increased public awareness of the possible consequences 
of seemingly mild symptoms should be carefully propagated. 
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Samenvatting 
De niet geregistreerde morbiditeit met betrekking tot OAD (Obstructive Airway 
Diseases = obstructieve ziekten van de luchtwegen) was het belangrijkste 
onderwerp van dit proefschrift. Het feit dat er in de algemene populatie 
personen zijn met tekenen en symptomen van OAD die niet als zodanig zijn 
gediagnostiseerd kan duiden op een mogelijke tekortkoming in de huidige 
medische praktijk. Hoewel er steeds meer consensus is met betrekking tot 
diagnose en therapie van astma en chronische obstructieve longziekten, kan 
deze kennis alleen maar worden toegepast op de geregistreerde morbiditeit. De 
niet geregistreerde morbiditeit van vandaag kan uiteindelijk leiden tot problemen 
in de de toekomst. In dit proefschrift is speciaal aandacht besteed aan de 
mogelijkheid om actief in een vroeg stadium personen met een milde vorm van 
OAD op te sporen door middel van screening van de algemene populatie. Het 
doel van actieve opsporing is om toepassing van richtlijnen met betrekking tot 
diagnose en therapie van astma en chronische obstructieve longziekten mogelijk 
te maken voor alle personen met een milde niet-manifeste vorm van de ziekte 
om zodoende de morbiditeit en mortaliteit terug te dringen en op lange termijn 
de prognose in de toekomst te verbeteren. 
Hoofdstuk 2 kan worden beschouwd als het basisonderzoek van dit proefschrift. 
In dit hoofdstuk hebben we gemeten wat de omvang is van het probleem van 
niet gediagnostiseerde ziekten van de luchtwegen. We hebben de resultaten van 
onze screening in 1992 vergeleken met die van een soortgelijke screening die in 
dezelfde regio in 1977 werd uitgevoerd. Een dwarsdoorsnedevergelijking van de 
twee onderzoeken toonde aan dat in 1992 ongeveer 65% van de personen bij 
wie tekenen van OAD werden ontdekt niet bekend waren bij de respectievelijke 
huisartsen. Bij het merendeel van deze personen bleek het te gaan om een milde 
vorm van de ziekte. Om een vergelijking tussen de twee onderzoeken te 
vergemakkelijken werd de term 'OAD" gedefinieerd volgens epidemiologische 
criteria die in 1977 werden gebruikt. Volgens huidige criteria konden deze 
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personen worden gedefinieerd als patiënten met een zeer milde, subklinische 
vorm van de ziekte. Dit onderzoek is ook een bevestiging van de toename in 
prevalentie van O AD die in de literatuur wordt gerapporteerd. Dit onderzoek 
toonde aan dat de toename niet uitsluitend kan worden toegeschreven aan het 
feit dat artsen en patiënten zich meer bewust zijn van de ziekte. Een toename in 
de pathologie van de luchtwegen kan daarom ook een rol spelen. Met nadruk 
dient gezegd te worden dat deze toename in prevalentie voornamelijk werd 
veroorzaakt door zeer milde gevallen. De conclusie kan worden getrokken dat 
niet geregistreerde morbiditeit met betrekking tot OAD voor ongeveer 65% 
bestaat uit patiënten met een zeer milde vorm van de ziekte. Hierdoor dient zich 
de keuzemogelijkheid aan om de algemene populatie te screenen teneinde 
secundaire preventie van OAD mogelijk te maken. 
In Hoofdstuk-3 hebben we onderzocht wat de invloed is van de perceptie van 
kortademigheid en psychologische kenmerken als mogelijke redenen voor het 
bestaan van niet geregistreerde OAD. Van de 1155 volwassen personen die 
werden gescreend hadden er 439 ooit kortademigheid ervaren. Van deze 
personen had slechts 28% hiervoor ooit de huisarts geconsulteerd. Van de 
personen met een goede perceptie van kortademigheid consuteerden er bijna 
twee keer zoveel de huisarts als van die met een slechte perceptie. De meest 
waarschijnlijke psychologische factoren hadden geen significante invloed op de 
keuze van de patiënt de huisarts te consulteren voor kortademigheid. Op basis 
van deze resultaten werd de conclusie getrokken dat onderrapportage van 
symptomen een belangrijke factor is die bijdraagt aan niet geregistreerde 
morbiditeit in de populatie. Het ontbreken van een juiste perceptie van 
ademnood is er wellicht de oorzaak van dat de huisarts niet wordt 
geconsulteerd. 
Hoofdstuk-4 kan worden beschouwd als de belangrijkste studie van dit 
proefschrift. We hebben onderzocht hoe doeltreffend screening van de algemene 
populatie is voor het opsporen van niet geregistreerde morbiditeit. We hebben 
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aangetoond dat de screeningscriteria die ¡η dit onderzoek worden voorgestaan 
geschikt waren bij het actief opsporen van personen met een milde maar 
aanhoudend verminderde FEV,. Deze voortdurend lage FEV, kan het resultaat 
zijn van een snelle afname in longfunctie gedurende de voorgaande jaren of het 
kan het resultaat zijn van een lager plateau dat tijdens de jong volwassen jaren 
werd bereikt. Uit dit onderzoek blijkt eveneens dat door middel van dit 
screeningsonderzoek personen met een snelle afname niet onderscheiden 
kunnen worden van personen met een normale afname. Dit leidt tot twee 
conclusies. Ten eerste, screening van de algemene populatie door middel van 
een eenvoudige test (een vragenlijst met betrekking tot respiratoire symptomen 
en spirometrie) is een effectieve methode om personen met een milde maar 
aanhoudend verminderde longfunctie op te sporen. Ten tweede, personen met 
een snelle afname in longfunctie kunnen niet worden opgespoord door middel 
van een screeningsonderzoek. Voor deze personen is monitoring van de 
longfunctie wellicht noodzakelijk om de afname nauwkeurig vast te kunnen 
stellen. 
De hoofdstukken 5, 6 en 7 kunnen worden gezien als een nauwkerig onderzoek 
van de instrumenten die de huisarts tot zijn beschikking heeft om personen met 
een indicatie voor behandeling in een vroeg stadium op te sporen. 
In Hoofstuk-5 hebben we bestudeerd wat de klinische relevantie is van vragen 
met betrekking tot bronchiale hyperreactiviteit (BHR) en allergie bij het opsporen 
van personen met een indicatie voor behandeling. Aangetoond werd dat een 
negatief antwoord op vragen over óf BHR óf allergie in het merendeel van de 
gevallen duidde op de afwezigheid van enige vorm van OAD die mogelijk 
behandeling behoefde. Een positief antwoord op een van deze vragen bleek een 
beperkte klinische relevantie te hebben en extra diagnostische tests zouden 
nodig zijn. Vragen met betrekking tot BHR en allergie zouden de huisarts dan 
ook helpen bij het selecteren van patiënten voor wie verdere metingen in het 
longfuctielaboratorium (PC20 en allergietests) mogelijk noodzakelijk zijn. 
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Bovenstaande informatie kan de onzekerheid wegnemen die een huisarts zou 
kunnen hebben bij het aanvragen van verdere diagnostische tests, met name 
wanneer hij te maken heeft met patiënten die geen duidelijke respiratoire 
afwijkingen hebben. 
In Hoofdstuk-6 hebben we onderzocht wat het effect is van de frequentie van 
FEV, metingen en de noodzakelijke duur van de observatieperiode voor het 
opsporen van personen met een toegenomen afname in longfunctie. Dit werd 
gedaan door middel van een statistisch model. We ontdekten dat personen met 
een grotere afname in FEV, dan ± 160 ml/jaar, gemeten gedurende een periode 
van één jaar, in de overgrote meerderheid van de gevallen een abnormale 
afname in longfunctie hebben. Dit is echter niet het geval voor personen met 
een geringere afname, bijvoorbeeld 100 ml/jaar. Zij kunnen al dan niet een snelle 
afname in longfunctie hebben, aangezien er een hoog percentage fout-positieve 
resultaten is. Voor het diagnostiseren van een afwijking bij dergelijke personen is 
dan ook een observatieperiode van tenminste twee jaar nodig. Deze bevindingen 
kwamen overeen met de resultaten in hoofdstuk-4. Starten met behandelen op 
basis van een snelle afname ( ± 80 ml/jaar) gemeten gedurende een periode van 
één jaar is dan ook niet te rechtvaardigen. In dergelijke gevallen dient óf de 
follow-up periode met een jaar te worden verlengd of moeten aanvullende data 
zoals BHR en reversibiliteit in overweging genomen worden. Onze conclusie was 
dat FEV, metingen gedurende een periode van twee jaar met een frequentie van 
één keer per drie of 6 maanden voldoende is voor een betrouwbare diagnose 
van personen met een matig tot ernstig toegenome afname van de longfunctie. 
Benadrukt dient te worden dat deze personen zo spoedig mogelijk opgespoord 
moeten worden, aangezien zij het meeste baat hebben bij vroegtijdige 
behandeling. 
In Hoofdstuk-7 hebben we de waarde van longitudinale piekstroomgegevens 
onderzocht. In de huisartsenpraktijk wordt vaak gebruik gemaakt van de 
piekstroom en het is een waardevolle parameter in de dwarsdoorsnede evaluatie 
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van de longfunctie. Wij ontdekten echter dat er op lange termijn geen correlatie 
was tussen de piekstroom en de FEV,, welke tegenwoordig als de gouden 
standaard wordt beschouwd in de evaluatie van de longfunctie. De piekstroom 
kan dan ook niet worden gebruikt voor het opsporen van patiënten met een 
snelle afname in longfunctie, aangezien deze geen goede indicator is van de 
afname. Het is aan te bevelen om hiervoor in de huisartsenpraktijk gebruik te 
maken van draagbare spirometers, die eveneens de FEV, kunnen meten. 
Hoofdstuk-8 toont het effect van behandeling van patiënten met een milde vorm 
van de ziekte die werden opgespoord door middel van screening van de 
algemene populatie. Actieve opsporing van personen met een milde vorm van de 
ziekte zou een verspilling van tijd betekenen als er geen adequate behandeling 
voorhanden was. Hoewel algemeen bekend is dat inhalatie-corticosteroïden 
(tijdelijk) de FEV, kunnen verhogen bij patiënten met manifest astma, is er in de 
literatuur geen enkele ervaring met het behandelen van personen die actief 
werden opgespoord door middel van screening. In Hoofdstuk-8 wordt een 
prospectief, placebo-gecontroleerd onderzoek gepresenteerd over de 
werkzaamheid van inhalatie-steroïden bij het behandelen van patiënten met een 
milde vorm van OAD die werden opgespoord door middel van screening van de 
algemene populatie. Deze personen werden gekenmerkt door de aanwezigheid 
van respiratoire symptomen, een verminderde FEV, (72% van de voorspelde 
FEV,) en een toegenomen hyperreactiviteit (PC20 was 2,46 mg/ml histamine). Na 
behandeling met inhalatie-steroïden vertoonden de FEV, en de PC20 een 
significante verbetering van respectievelijk 76 ml (p = 0,02) en 1,4 dosisstap 
histamine (p = 0,002). Het aantal exacerbaties in de steroïdegroep was vijf keer 
lager dan in de placebogroep. Vanwege het kleine aantal deelnemers was dit 
verschil echter statistisch gezien niet significant. Er was geen significante 
verbetering in symptomen of piekstroom. De conclusie kan dan ook worden 
getrokken dat de verslechterde longfunctie en de toegenomen BHR van 
personen met een OAD die worden opgespoord door screening van de algemene 
populatie kunnen worden verbeterd door behandeling met inhalatie Steroiden. 
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Conclusie 
Er ¡s behoefte aan actieve opsporing van patiënten met OAD en de bestaande 
opsporingsmethodes en follow-up moeten worden verfijnd. Patiënten met een 
milde vorm van OAD kunnen in een vroeg stadium worden opgespoord door 
middel van screening van de algemene populatie. Deze patiënten kunnen op een 
effectieve manier worden behandeld met inhalatie-corticosteroïden. 
Aanbevelingen 
1. Screening van de populatie bleek een effectieve methode voor het in 
een vroeg stadium opsporen van personen met een milde vorm van 
OAD. In de huisartsenpraktijk is het echter niet haalbaar ieder individu 
in de populatie te screenen. Er dient dan ook aandacht te worden 
besteed aan actieve 'case-finding" onder personen bij wie 
risicofactoren bekend zijn. Aan patiënten die de huisarts consulteren 
dient, ongeacht de reden voor consultatie, een vragenlijst betreffende 
respiratoire symptomen te worden gegeven die ze in kunnen vullen als 
ze op de afspraak wachten. Deze vragenlijst dient informatie te 
bevatten over hoesten, het opgeven van sputum, dyspnoe, piepende 
ademhaling, allergie, aspecifieke bronchiale hyperreactiviteit, een 
positieve familieanamnese en rookgewoontes. 
2. Het is aan te bevelen de FEV1 te meten bij alle personen die positief 
gereageerd hebben op een van de onderdelen van de vragenlijst. 
Spirometrie dient te worden uitgevoerd met behulp van betrouwbare, 
gekalibreerde apparatuur volgens standaard procedures door personen 
die van tevoren getraind zijn. Dit is essentieel omdat de FEV, binnen 
personen een grote variabiliteit vertoont. 
3. Patiënten moeten drie tot zes maanden later opnieuw gemeten worden 
om de voorafgaande bevindingen te bevestigen. Op deze manier is het 
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mogelijk om de personen die een aanhoudend verslechterde 
longfunctie hebben zonder enige verdere vertraging te identificeren en 
te behandelen. 
4. Het is aan te bevelen in de huisartsenpraktijk draagbare spirometers te 
gebruiken voor het meten van de FEV,. Dergelijke spirometers zijn 
nauwkeurig, gemakkelijk in het gebruik en, wat belangrijker is, 
betaalbaar. Aangezien de meeste praktijken tegenwoordig zijn 
uitgerust met computers, zou in overweging genomen kunnen worden 
meer te investeren in longfunctiesoftware. 
5. Gedurende de huisartsenopleiding dient er nadrukkelijker aandacht 
besteed te worden aan actieve "case-finding". Het is belangrijk dat de 
huisarts overtuigd is van de waarde hiervan. 
6. Gepoogd dient te worden om onderpresentatie van symptomen te 
verminderen. Zorgvuldig moet geprobeerd worden het publiek meer en 
meer bewust te maken van de mogelijke gevolgen van schijnbaar 
milde symptomen. 
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Stellingen 
Active detection of obstructive airways disease 
in the general population 
1 Under-presentation of respiratory symptoms is a major factor contributing to the 
unregistered morbidity of obstructive airways disease (OAD). 
2 The effect of a medical history on respiratory symptoms is potentiated when 
combined with spirometry. 
3 The peak flow is not a good indicator of the annual decline in lung function. 
4 Inhaled steroids are beneficial in treating patients with mild OAD, even at an 
early stage. 
5 Never treat the lung function, treat the patient. С van Weel 
6 Confront the disease at it's first stage. Aulus Flaccus Persius 34-62 AD. 
7 We have made great medical progress in the last generation. What used to be 
merely an itch is now an allergy. (Anonymous) 
8 Hay fever is the real flower power. Leonard Louis Levinson 
9 Asthma is a disease that has practically the same symptoms as passion except 
that with asthma it lasts longer. (Anonymous) 
10 Medical statistics is like a bikini. What it reveals is interesting but what it covers 
is vital (Anonymous). 
11 An unwelcome adverse effect of screening is the major glaxonification of the 
general population. 
12 Epidemiologists are nice people, but do not let them treat you. Modified from 
August Bier 1861-1949 
13 Nothing hinders a cure so much as frequent change of medicine. Seneca; 4 BC-
65 AD. 
14 After twenty years one is no longer quoted in medical literature. Every twenty 
years one sees a republication of the same ideas. Béla Schick (1877-1967) 
15 Every reason by the government against a total ban on tobacco depicts its 
reluctance to kill the goose with the golden eggs. 
16 Humansl noxious, filthy humans, but I love them. H.D. Mite 
17 The clinician learns less and less about more and more until there's nothing more 
to learn about everything and the researcher learns more and more about less 
and less until he learns everything about nothing. 



